Neurodevelopmental Disorder with Early-Onset Parkinsonism and Behavioral Abnormalities

Mendelian MONDO:0958323 Pathograph 39 Show in embeddings browser Neurodevelopmental Disorder Movement Disorder Autosomal Recessive Early-Onset Parkinsonism

Neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities (NEDPBA; OMIM 620747) is an ultra-rare autosomal recessive condition caused by biallelic loss-of-function variants in PTRHD1 (peptidyl-tRNA hydrolase domain containing 1) at 2p23.3. Its defining feature is a biphasic course in which a single locus appears to bridge neurodevelopment and neurodegeneration; the reporting authors put this no more strongly than a potential role for the protein in both. In the first phase, delayed developmental milestones become apparent in late infancy or early childhood and settle into a static, non-progressive impairment of intellectual development with learning difficulties, speech and language delay, and prominent behavioral abnormalities (attention deficit and hyperactivity, aggression, social isolation, obsessive-compulsive behavior, anxiety, and sleep disturbance). In the second phase - typically the third or fourth decade, but reported from later childhood onward - a progressive motor disorder emerges, combining parkinsonism (bradykinesia, rest and postural tremor, rigidity, postural instability) with pyramidal signs (spasticity and hyperreflexia); some individuals additionally develop dementia, gait ataxia, or generalized epilepsy. Parkinsonism has been described as levodopa-responsive in most reported patients, and the intrafamilial variability in both the presence and the timing of motor features is a consistent finding. Fewer than a dozen families have been reported worldwide - from Iran, Oman, Pakistan, South Africa, Austria, and Italy, most but not all of them consanguineous - and the molecular function of PTRHD1 remains genuinely unknown: despite the PTH2 (peptidyl-tRNA hydrolase 2) domain that gives the gene its name, the recombinant human protein binds tRNA but has no detectable peptidyl-tRNA hydrolase activity. The leading (but still unproven) mechanistic hypothesis is that the PTH2/ubiquitin-like-domain-binding module links PTRHD1 to the ubiquitin-proteasome system, a pathway already implicated in both intellectual disability and early-onset parkinsonism.

Ask OpenScientist

Ask a research question about Neurodevelopmental Disorder with Early-Onset Parkinsonism and Behavioral Abnormalities. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
7
Pathophys.
27
Phenotypes
1
Hypotheses
4
Gaps
39
Pathograph
1
Genes
3
Variants
3
Medical Actions
5
Differentials
4
References
1
Deep Research
🏷

Classifications

Harrison's Part
NEUROLOGIC GENETICS ENVIRONMENT DISEASE
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
All reported families carry biallelic (homozygous) PTRHD1 variants that segregate with disease in a recessive pattern. Parental consanguinity is documented in all ten families in the most recent published tally, and ascertainment has been mainly in consanguineous kindreds of Middle Eastern or African origin, but consanguinity is not reported for the Austrian singleton or the Italian family, so it is characteristic rather than universal. Heterozygous carriers, including obligate-carrier parents, are unaffected.
Autosomal recessive inheritance
Show evidence (2 references)
PMID:30398675 SUPPORT Human Clinical
"Together with the previous reports, we provide conclusive evidence that loss-of-function mutations in PTRHD1 cause autosomal-recessive juvenile parkinsonism and intellectual disability."
States the autosomal recessive mode of inheritance for PTRHD1 loss-of-function disease with genome-wide significant linkage support.
PMID:41722179 SUPPORT Human Clinical
"Mutations in PTRHD1 have recently been implicated in autosomal recessive neurodevelopmental syndromes characterized by intellectual disability, and variably penetrant early-onset parkinsonism, mainly in consanguineous families of Middle Eastern or African origin."
Independent confirmation of recessive inheritance and of the variable penetrance of the parkinsonian arm.
◈

Mechanistic Hypotheses

1
PTH2/UBL-Domain Link to Ubiquitin-Proteasome System Failure
ptrhd1_ubiquitin_proteasome_model EMERGING
Evidence balance 4 support
The leading - but explicitly unproven - mechanistic model. PTRHD1 consists essentially of a PTH2 (peptidyl-tRNA hydrolase 2) domain, and every disease-associated allele lies within or truncates it. In yeast, the Pth2 protein is a ubiquitin-like (UBL) domain-binding protein that participates in the ubiquitin-proteasome pathway and retards ubiquitin-mediated degradation. Because the ubiquitin-proteasome system is independently implicated both in intellectual disability (UBE3A, UBE2A, CUL4B, BRWD3) and in early-onset parkinsonism (parkin/PRKN, FBXO7), the proposal is that PTRHD1 loss of function degrades proteostasis in a way that impairs brain development and later renders vulnerable neuronal populations degeneration-prone. The originating authors state this as speculation, no disease-specific proteasome assay has been reported in patient neurons, and the alternative that PTRHD1 acts in translation-associated RNA quality control is not excluded.
Pathograph links
PTRHD1 Biallelic Loss of Function -> Impaired Ubiquitin-Proteasome Protein Quality Control INDIRECT UNKNOWN INTERMEDIATES Hypothesized link, based on the UBL-domain-binding activity of the PTH2 domain family; not demonstrated in patient neurons.
Impaired Ubiquitin-Proteasome Protein Quality Control -> Disrupted Development of Cognitive and Behavioral Circuits INDIRECT UNKNOWN INTERMEDIATES
Impaired Ubiquitin-Proteasome Protein Quality Control -> Nigrostriatal Dopaminergic Neuron Degeneration INDIRECT UNKNOWN INTERMEDIATES
Show evidence (4 references)
PMID:27753167 SUPPORT Other
"we speculated that PTRHD1 genetic variability might cause ID and parkinsonism through defects in the ubiquitin-proteasome system, as observed in other inherited forms of parkinsonism and ID."
The originating statement of the hypothesis, explicitly framed by its authors as speculation rather than demonstrated mechanism.
PMID:27753167 SUPPORT Other
"The PTH2 domain is a ubiquitin-like (UBL) domain-binding protein that is known to participate in the ubiquitin-proteasome pathway and has been shown to suppress ubiquitin-mediated degradation."
Provides the domain-level biochemical rationale (from yeast Pth2) that motivates the hypothesis; it is homology-based, not PTRHD1-specific.
PMID:34630269 SUPPORT Other
"Intriguingly, the pathogenic variants causing Parkinsonism are in the ubiquitin-like (UBL) domain-binding site of the protein."
Independent review notes that the disease alleles cluster in the UBL-domain-binding site, the structural argument for the hypothesis.
+ 1 more reference
?

Discussions and Knowledge Gaps

4
What is the actual molecular function of human PTRHD1, given that the recombinant protein binds tRNA but has no peptidyl-tRNA hydrolase activity despite carrying the PTH2 domain that names the gene?
KNOWLEDGE GAP ptrhd1_molecular_function_unknown
Attached to
pathophysiology#Impaired Ubiquitin-Proteasome Protein Quality Control
This is the central gap for the entire entry. The gene name and the ubiquitin-proteasome hypothesis both derive from the PTH2 domain, but the only direct biochemical characterization of the human protein found tRNA binding without hydrolase activity and concluded that PTRHD1 is not a peptidyl-tRNA hydrolase. No enzymatic activity, physiological substrate, or binding partner has been established for the human protein, and no disease-specific proteasome-function assay has been reported in PTRHD1 patient neurons. Until this is resolved, every mechanistic node downstream of the genetic lesion is inferential, and the ubiquitin-proteasome model rests on yeast Pth2 homology rather than human data.
Proposed experiments
PTRHD1 neuronal interactome by AP-MS
ptrhd1_interactome
Determine binding partners of human PTRHD1 by affinity purification-mass spectrometry in neuronal cells, testing specifically for UBL-domain proteins (RAD23, UBQLN/DSK2 homologs) and proteasome subunits.
Decision criterion
Recovery of UBL-domain proteins or proteasome subunits as reproducible specific interactors would support the ubiquitin-proteasome model; their absence alongside recovery of ribosome/tRNA-handling partners would favor a translation-associated quality-control function instead.
Proteasome function in patient-derived neurons
ptrhd1_proteasome_activity
Measure proteasome activity and steady-state polyubiquitinated-protein load in patient-derived fibroblasts and iPSC-derived cortical and midbrain dopaminergic neurons carrying p.Ala57Argfs*26 versus isogenic controls.
Decision criterion
Reduced chymotrypsin-like proteasome activity or accumulation of polyubiquitinated protein in patient neurons would upgrade the Impaired Ubiquitin-Proteasome Protein Quality Control node from HYPOTHETICAL toward ESTABLISHED.
Null versus stable-truncation allele comparison
ptrhd1_null_vs_truncation
Test whether the stable truncated p.Ala57Argfs*26 protein acts as a null or exerts a distinct (dominant-negative or neomorphic) activity, by comparing a full knockout with a knock-in of the frameshift allele in the same isogenic background.
Decision criterion
A phenotypic difference between full knockout and frameshift knock-in would show that the stable truncated protein is not simply a null, which would change how the Escape of Nonsense-Mediated Decay node is interpreted mechanistically.
Show evidence (1 reference)
PMID:27235175 SUPPORT In Vitro
"Additionally, we report binding to tRNA but absence of peptidyl-tRNA hydrolase activity. Thus, PTRHD1 is not a Pth and the functional consequence of nucleotide binding remains undefined."
The primary biochemical result establishing that the nominal function implied by the gene name does not hold, leaving the true function unknown.
Is the parkinsonism of PTRHD1 disease actually caused by nigrostriatal dopaminergic neurodegeneration? No neuropathological examination and no dopamine-transporter imaging study has ever been published for a PTRHD1-mutant individual.
KNOWLEDGE GAP ptrhd1_no_neuropathology_or_dat_imaging
Attached to
pathophysiology#Nigrostriatal Dopaminergic Neuron Degeneration
The Nigrostriatal Dopaminergic Neuron Degeneration node - and the conforms_to link to the parkinsonism_dopaminergic_degeneration module - is currently supported only indirectly, by levodopa responsiveness and by PTRHD1 expression in the substantia nigra, striatum and putamen. Brain MRI is grossly normal and DaTscan was explicitly unavailable in the one detailed report that mentions it. The distinction matters mechanistically: a genuinely degenerative nigral lesion would place this disorder alongside the other recessive early-onset parkinsonisms, whereas a developmental or functional dopaminergic deficit that becomes symptomatic with age would make it a different kind of entity - and this is exactly the neurodevelopment versus neurodegeneration question that makes the disorder interesting.
Proposed experiments
Presynaptic dopaminergic imaging in PTRHD1 carriers
ptrhd1_dat_imaging
Perform dopamine transporter SPECT (DaT-SPECT) or 18F-DOPA PET in PTRHD1-mutant individuals before and after the emergence of parkinsonism, to test for presynaptic dopaminergic denervation and to date its onset relative to motor symptoms.
Decision criterion
Reduced striatal tracer binding that worsens with motor progression would confirm presynaptic nigrostriatal degeneration; normal binding in symptomatic individuals would refute the degenerative model and point to a postsynaptic or circuit-level mechanism.
Post-mortem neuropathology of a PTRHD1 brain
ptrhd1_neuropathology
Obtain post-mortem neuropathological examination of a PTRHD1-mutant brain, assessing nigral neuronal counts, alpha-synuclein/Lewy pathology, tau, and ubiquitin-positive inclusions.
Decision criterion
Nigral neuronal loss would establish the degeneration node; the presence or absence of ubiquitin-positive inclusions would additionally test the ubiquitin-proteasome hypothesis directly in human tissue.
Show evidence (2 references)
PMID:34765690 SUPPORT Human Clinical
"DaTscan imaging is not available."
Documents the absence of dopaminergic imaging in the one patient in whom parkinsonism was formally rated.
PMID:36699000 SUPPORT Human Clinical
"Results of dopaminergic imaging and response to antiparkinsonian medication often supported the neurodegenerative nature of parkinsonism."
Shows that the class-level expectation is neurodegeneration, which makes the absence of PTRHD1-specific imaging and pathology data a concrete, answerable gap rather than an open-ended question.
No animal or human cellular model of PTRHD1 deficiency has been reported that reproduces either arm of the biphasic phenotype. Can a model recapitulate the neurodevelopmental phase, the later motor-degenerative phase, or the transition between them?
KNOWLEDGE GAP ptrhd1_no_animal_or_cellular_model
Attached to
pathophysiology#PTRHD1 Biallelic Loss of Function
All published PTRHD1 work is human genetic or descriptive; the only laboratory studies are a recombinant-protein biochemistry paper and patient-lymphocyte transcript/protein analyses. Without a model system, the causal chain from the genetic lesion to either phenotype cannot be tested, and no therapeutic hypothesis beyond symptomatic levodopa can be evaluated. The biphasic course makes this disorder an unusually informative potential model for how a single locus can produce a static developmental deficit and a later progressive degeneration, which raises the value of building one.
Proposed experiments
Isogenic iPSC-derived cortical and dopaminergic neuron models
ptrhd1_ipsc_neurons
Generate isogenic PTRHD1-null and patient-allele knock-in human iPSC lines and differentiate them to cortical neurons and midbrain dopaminergic neurons, phenotyping neurite development, synapse formation, proteasome function, and long-term survival under stress.
Decision criterion
A developmental phenotype in cortical neurons together with a later-emerging survival deficit in dopaminergic neurons would reproduce the biphasic human course in vitro and validate the two-arm pathograph.
Aged vertebrate PTRHD1 loss-of-function model
ptrhd1_vertebrate_model
Create PTRHD1 knockout and knock-in vertebrate models (mouse and/or zebrafish) with longitudinal cognitive, behavioral, and motor phenotyping into aged animals to test whether a late motor phase emerges on a developmental background.
Decision criterion
Emergence of a late motor phenotype on a background of early cognitive or behavioral abnormality would establish the first animal model of the neurodevelopment-to-neurodegeneration transition for this gene.
Show evidence (1 reference)
PMID:34765690 SUPPORT Other
"However, to date, functional studies of the reported variants and studies of patients' derived cells were not performed."
Scopes the gap to the pre-2021 literature: at the time of this report no functional study of any PTRHD1 disease allele had been performed. This same paper then supplied the first patient-derived-cell data (NMD escape, stable truncated protein), but no animal model and no engineered cellular model of PTRHD1 deficiency has been reported before or since.
Is the parkinsonian arm incompletely penetrant, or merely very late, so that all biallelic carriers would eventually develop it if followed long enough?
OPEN QUESTION ptrhd1_parkinsonism_penetrance
Attached to
pathophysiology#Nigrostriatal Dopaminergic Neuron Degeneration
Reports differ. Some describe parkinsonism as variably penetrant; in one Omani family only one of four affected siblings had developed mild parkinsonism by the fourth decade, and in an Iranian family the affected individuals were reported with intellectual disability manifestations. Yet the longest-followed kindred showed motor signs appearing only at ages 34-48, with the authors concluding that gait problems may not be evident until towards the end of the fourth decade. Distinguishing true incomplete penetrance from ascertainment at too young an age changes both counseling and the interpretation of the mechanism (a stochastic degenerative threshold versus an obligate but slow decline).
Proposed experiments
Prospective re-examination of known PTRHD1 kindreds
ptrhd1_penetrance_cohort
Systematic prospective re-examination of all reported PTRHD1 kindreds at 5-year intervals with standardized movement-disorder assessment, to establish age-specific penetrance curves for parkinsonism.
Decision criterion
A penetrance curve approaching 100% by the fifth or sixth decade would support age-dependent rather than incomplete penetrance; a plateau well below 100% would establish genuinely incomplete penetrance and motivate a search for modifiers.
Show evidence (2 references)
PMID:41918506 SUPPORT Human Clinical
"Our findings reveal that not all PTRHD1 mutations manifest with muscle rigidity and postural instability and confirm that gait problems may not be evident until towards the end of the fourth decade."
Supports the very-late-rather-than-absent interpretation, and documents the incomplete parkinsonian syndrome.
PMID:34816696 SUPPORT Human Clinical
"Our findings are in agreement with the clinical spectrum of PTRHD1 mutations; however, our affected individuals suffer from ID manifestations."
A family in whom intellectual disability was the reported manifestation, without documented parkinsonism, supporting variable expression of the motor arm.
⚙

Pathophysiology

7
PTRHD1 Biallelic Loss of Function
Homozygous missense, frameshift, or nonsense variants in the single PTH2 domain of PTRHD1 (2p23.3) abolish or corrupt the function of the 140-amino-acid protein. Linkage-supported segregation in multiple unrelated consanguineous families, absence of the alleles from ethnically matched control chromosomes and population databases, and the presence of clearly truncating alleles together establish loss of function as the disease mechanism. PTRHD1 is widely expressed, including throughout the adult brain (cortex, cerebellum, brainstem, substantia nigra, pons, putamen, and spinal cord), which is consistent with a phenotype that spans cognitive, behavioral, pyramidal, and extrapyramidal domains.
PTH2/UBL-Domain Link to Ubiquitin-Proteasome System Failure
PTRHD1 hgnc:33782 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PTRHD1 (hgnc:33782). hgnc:33782 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Escape of Nonsense-Mediated Decay with Stable Truncated Protein Truncating PTRHD1 alleles do not simply eliminate the transcript; the mutant mRNA is stable and a shortened protein is produced.
Impaired Ubiquitin-Proteasome Protein Quality Control Hypothesized link, based on the UBL-domain-binding activity of the PTH2 domain family; not demonstrated in patient neurons. PTH2/UBL-Domain Link to Ubiquitin-Proteasome System Failure
Disrupted Development of Cognitive and Behavioral Circuits The first, static phase of the biphasic course: developmental milestones are delayed from late infancy and cognitive/behavioral impairment is then non-progressive.
Nigrostriatal Dopaminergic Neuron Degeneration The second, progressive phase, emerging years to decades after the developmental phase in the same individuals.
Corticospinal Tract Dysfunction Pyramidal involvement, present in some families from childhood alongside the developmental phase and progressive in others.
Gait ataxia Reported as mildly ataxic and explicitly NOT parkinsonian and NOT spastic, so it is not placed on either curated motor arm. The reporting authors suggest cerebellar or cerebellar-network involvement; no such node is curated because there is no imaging or pathological evidence for it.
Sensorimotor neuropathy Peripheral-nerve involvement lies outside both the nigrostriatal and the corticospinal arms and has no curated mechanism; it is attached to the root lesion to record that it is unexplained.
Hypersomnia Excessive sleepiness is reported alongside the motor and behavioral features but cannot be assigned to a specific curated arm.
Generalized-onset seizure Single-case epilepsy, proposed as a spectrum extension; no epileptogenic mechanism is curated for PTRHD1.
Exotropia Single-family finding with no curated mechanism.
Pectus excavatum Single-family skeletal finding with no curated mechanism; PTRHD1 is widely expressed outside the nervous system, but no connection has been shown.
Show evidence (2 references)
PMID:30398675 SUPPORT Human Clinical
"Together with the previous reports, we provide conclusive evidence that loss-of-function mutations in PTRHD1 cause autosomal-recessive juvenile parkinsonism and intellectual disability."
Establishes biallelic loss of function as the causal molecular lesion.
PMID:41918506 SUPPORT Human Clinical
"PTRHD1 is expressed in many organs, and we found widespread expression in the adult brain."
Expression data supporting a broadly distributed CNS substrate for the loss-of-function lesion.
Escape of Nonsense-Mediated Decay with Stable Truncated Protein
Functional work on the recurrent c.169_196del (p.Ala57Argfs*26) allele in primary cells from four affected members of an Omani family showed that, contrary to in-silico prediction, the premature-termination-codon transcript escapes nonsense-mediated mRNA decay and is in fact expressed at higher levels than wild type. Immunoblot and isoelectric focusing detected a stable truncated protein of roughly 8-9 kDa (isoelectric point ~11) instead of the 15 kDa wild-type product. The disease allele therefore produces an abnormal protein species rather than protein absence, which leaves open whether the pathogenic effect is pure loss of function or includes an aberrant activity of the truncated product.
Show evidence (2 references)
PMID:34765690 SUPPORT In Vitro
"We further confirmed the apparent transcript escape of the nonsense-mediated messenger RNA (mRNA) decay pathway."
Direct patient-cell demonstration of NMD escape.
PMID:34765690 SUPPORT In Vitro
"Western blotting and isoelectric focusing identified a truncated, but stable mutant PTRHD1 protein expressed in the patient"
Shows the truncated protein is stably expressed in patient primary cells, so the allele is not a protein-null.
Impaired Ubiquitin-Proteasome Protein Quality Control
Hypothesized proximal consequence of PTRHD1 loss of function. The PTH2 domain family binds ubiquitin-like (UBL) domains and participates in the ubiquitin-proteasome pathway, and all reported disease alleles fall within that domain - although since PTH2 spans residues 25-139 of a 140-amino-acid protein, that localization is a weak constraint. A secondary review adds that the parkinsonism-causing variants sit in the UBL-domain-binding site, but it was written before p.Arg122Gln, p.Arg122Trp and p.Tyr71* were reported and so cannot speak to the full allele set. Disturbed ubiquitin-dependent proteolysis would plausibly account for the double phenotype, since the ubiquitin-proteasome system is required for brain development, synaptic plasticity, and long-term memory formation, and its failure is a recognized route to both intellectual disability and early-onset parkinsonism. No proteasome-activity or polyubiquitinated-protein measurement has been reported in PTRHD1-deficient human neurons, so this node remains a hypothesis rather than a demonstrated step.
PTH2/UBL-Domain Link to Ubiquitin-Proteasome System Failure
proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043161 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161). GO:0043161 is a biological process from the Gene Ontology. ↓ DECREASED ubiquitin-dependent protein catabolic process GO:0006511 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated ubiquitin-dependent protein catabolic process (GO:0006511). GO:0006511 is a biological process from the Gene Ontology. ↕ DYSREGULATED
Downstream
Disrupted Development of Cognitive and Behavioral Circuits PTH2/UBL-Domain Link to Ubiquitin-Proteasome System Failure
Nigrostriatal Dopaminergic Neuron Degeneration PTH2/UBL-Domain Link to Ubiquitin-Proteasome System Failure
Show evidence (2 references)
PMID:27753167 SUPPORT Other
"the role that the ubiquitin proteasome system plays in brain development, synaptic plasticity, and long-term memory formation"
States the biological rationale linking a UPS defect to the neurodevelopmental arm of the phenotype; not PTRHD1-specific experimental evidence.
PMID:36699000 SUPPORT Human Clinical
"Proposed disease mechanisms included aberrant mitochondrial function and disruptions in neurotransmitter metabolism, endosomal trafficking, and the autophagic-lysosomal and ubiquitin-proteasome system."
Places ubiquitin-proteasome failure among the recurrent proposed mechanisms across genetic neurodevelopmental disorders with parkinsonism, the disease class to which this entry belongs.
Disrupted Development of Cognitive and Behavioral Circuits
The first arm of the biphasic course. Loss of PTRHD1 during brain development produces delayed milestones from late infancy, mild to severe impairment of intellectual development, speech and language delay, and a characteristic behavioral profile (attention deficit and hyperactivity, impulsivity, aggression, social isolation, obsessive-compulsive behavior, anxiety, and sleep disturbance). Critically, this arm is STATIC: cognitive impairment in the best-followed family was explicitly described as early-onset and non-progressive, in contrast to the later motor arm. Brain MRI is grossly unremarkable, so the substrate is presumed to be circuit- and synapse-level rather than a gross malformation.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
nervous system development GO:0007399 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal nervous system development (GO:0007399). GO:0007399 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Global developmental delay Delayed attainment of motor, speech and social milestones is the earliest clinical expression of the disrupted developmental program.
Impaired intellectual development The cognitive outcome of the developmental arm, static once established.
Delayed speech and language development Language is disproportionately affected within the developmental arm.
Speech apraxia Motor-speech programming failure reported within the language phenotype.
Stuttering Dysfluency reported in the most severely affected sibling of one family.
Attention deficit hyperactivity disorder The attention and hyperactivity component of the behavioral arm.
Aggressive behavior Externalizing behavior reported in a subset of affected siblings.
Obsessive-compulsive behavior Compulsive rituals reported in one affected adult.
Anxiety Internalizing symptom reported among the recurrent behavioral features.
Depression Internalizing symptom reported among the recurrent behavioral features.
Sleep talking Sleep-related behavioral symptom reported in one family.
Show evidence (3 references)
PMID:34765690 SUPPORT Human Clinical
"All cases reported shared a consistent phenotype of delayed developmental milestones and moderate to severe ID. The onset of symptoms was present since late infancy."
Establishes the late-infantile onset of the developmental arm across all then-reported cases.
PMID:41918506 SUPPORT Human Clinical
"Early onset and nonprogressive ID in the four siblings were assessed as mild to moderate"
Key evidence that the cognitive arm is static rather than progressive - the feature that makes this a true neurodevelopment-to-neurodegeneration bridge rather than a single progressive dementia.
PMID:41918506 SUPPORT Human Clinical
"The behavioral symptoms range from hyperactivity, aggressive behavior, attention deficit, social isolation, and somniloquy (sleep-talking)."
Characterizes the behavioral-abnormality arm named in the disease label.
Nigrostriatal Dopaminergic Neuron Degeneration
Inferred second arm of the biphasic course. Years to decades after the static developmental phase, affected individuals develop progressive parkinsonism that in most reported patients has been levodopa-responsive, implying a presynaptic nigrostriatal dopaminergic deficit. PTRHD1 is expressed in the substantia nigra, striatum, and putamen, providing an anatomical substrate. This node is nonetheless marked HYPOTHETICAL and is a declared knowledge gap: no neuropathology has ever been reported for a PTRHD1 patient, and no dopamine-transporter (DaT-SPECT) imaging result has been published - the Omani proband with parkinsonism explicitly had no DaTscan available. Conformance to the shared parkinsonism_dopaminergic_degeneration module is therefore asserted on pharmacological and expression grounds, not on direct demonstration of nigral cell loss in this disease.
midbrain dopaminergic neuron CL:0000700 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves midbrain dopaminergic neuron, annotated with dopaminergic neuron (CL:0000700). CL:0000700 is a cell type from the Cell Ontology.
substantia nigra pars compacta UBERON:0001965 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in substantia nigra pars compacta (UBERON:0001965). UBERON:0001965 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Striatal Dopamine Deficiency and Basal Ganglia Motor Circuit Dysfunction
Dementia Late cognitive decline appears in the same decade as the motor features, superimposed on the static developmental impairment. It is placed on the degenerative arm because of that temporal coupling; its anatomical substrate has never been examined in this disorder, so the intermediates are unknown.
Show evidence (3 references)
PMID:34765690 SUPPORT Human Clinical
"Most of these patients developed levodopa‐responsive parkinsonism symptoms around the third and fourth decade."
Reported for most of the seven patients in the three families known as of 2021. Levodopa responsiveness is indirect evidence of a presynaptic nigrostriatal dopaminergic deficit with preserved postsynaptic striatal targets; it does not itself demonstrate neuronal loss.
PMID:41918506 SUPPORT Human Clinical
"We found expression of PTRHD1 in different brain parts including the striatum and putamen, which are involved in degenerative neurological disorders."
Expression in the relevant basal-ganglia structures supports, but does not prove, a nigrostriatal locus of degeneration.
PMID:36699000 SUPPORT Human Clinical
"Results of dopaminergic imaging and response to antiparkinsonian medication often supported the neurodegenerative nature of parkinsonism."
Class-level evidence that in genetic neurodevelopmental disorders with parkinsonism (a group that explicitly includes PTRHD1) the motor arm is generally neurodegenerative rather than developmental; PTRHD1-specific imaging and neuropathology are still absent.
Striatal Dopamine Deficiency and Basal Ganglia Motor Circuit Dysfunction
Loss of nigrostriatal dopaminergic input unbalances the basal ganglia motor circuit, producing the clinical parkinsonian syndrome: bradykinesia with rest and postural tremor, muscle stiffness/rigidity, postural instability, and gait disturbance. The syndrome is levodopa-responsive in most reported patients, consistent with a dopamine-replaceable striatal deficit. It is also atypical in an important minority: one family developed bradykinesia, tremor and dementia in the fourth decade with neither muscle rigidity nor postural instability, and with a mildly ataxic rather than parkinsonian gait, widening the syndrome beyond pure parkinsonism.
dopamine secretion GO:0014046 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased dopamine secretion (GO:0014046). GO:0014046 is a biological process from the Gene Ontology. ↓ DECREASED
striatum UBERON:0002435 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in striatum (UBERON:0002435). UBERON:0002435 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Parkinsonism The clinical syndrome produced by the striatal dopamine deficit.
Bradykinesia The cardinal sign, required for the parkinsonism diagnosis in the reported families.
Resting tremor Rest tremor as part of the parkinsonian syndrome.
Postural tremor Postural tremor as part of the parkinsonian syndrome.
Rigidity Increased tone, present in some families and explicitly absent in others.
Postural instability Loss of postural reflexes, present in some families and explicitly absent in others.
Show evidence (2 references)
PMID:27753167 SUPPORT Human Clinical
"presented with ID, muscle stiffness, rest and postural tremor, postural instability, gait disturbances, speech difficulties, as well as psychiatric symptoms such as anxiety, hypersomnia, and hypersexuality."
Documents the full parkinsonian motor syndrome (stiffness, rest and postural tremor, postural instability, gait disturbance) in the index family.
PMID:41918506 SUPPORT Human Clinical
"There was no muscle rigidity and postural instability, but there were unusual features of exotropia, pectus excavatum, and prominent clavicles."
Counter-evidence delimiting the syndrome: in the Pakistani family the cardinal signs of rigidity and postural instability were absent even in the eldest affected sibling, so these are not obligate features.
Corticospinal Tract Dysfunction
A pyramidal arm that is separable from the parkinsonian arm and, in some families, precedes it by decades. Affected individuals in the South African and Omani kindreds developed generalized spasticity, brisk reflexes and upgoing toes in childhood, alongside the developmental phase; in the most severely affected individual this worsened over time to loss of independent ambulation. Notably, the pyramidal arm is not universal - the Pakistani family had a mildly ataxic gait explicitly without spasticity or hemiparesis - so spasticity is a frequent but not obligate feature.
corticospinal tract UBERON:0002707 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in corticospinal tract (UBERON:0002707). UBERON:0002707 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Spasticity Velocity-dependent hypertonia from loss of corticospinal inhibition.
Hyperreflexia Brisk deep tendon reflexes from the same upper-motor-neuron lesion.
Extensor plantar response Upgoing toes completing the pyramidal picture.
Show evidence (2 references)
PMID:34765690 SUPPORT Human Clinical
"all patients presented initially with global developmental delay during early childhood and onset of pyramidal signs including spasticity and hyperreflexia"
Establishes childhood-onset pyramidal involvement co-occurring with the developmental phase, before parkinsonism.
PMID:34765690 SUPPORT Human Clinical
"these patients developed pyramidal signs consisting of spasticity, hyperreflexia, and upgoing toes"
Enumerates the pyramidal signs across the then-reported cohort.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Neurodevelopmental Disorder with Early-Onset Parkinsonism and Behavioral Abnormalities Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

27
Musculoskeletal 3
Rigidity OCCASIONAL HP:0002063 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Rigidity (HP:0002063). HP:0002063 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:34630269 SUPPORT Human Clinical
"Phenotypes were variably complicated by muscle stiffness, postural tremor, pyramidal signs, sensory-motor polyneuropathy, behavioral disorders, and hypersomnia."
Review lists muscle stiffness among the variable complications, i.e. not universal.
PMID:41918506 REFUTE Human Clinical
"A hallmark of muscle rigidity, postural instability for parkinsonism did not develop even in the eldest patient aged 48 years."
Explicit counter-evidence: rigidity was absent in an entire family, justifying the OCCASIONAL rather than FREQUENT band.
Spasticity FREQUENT HP:0001257 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spasticity (HP:0001257), qualified as course progressive; childhood onset. HP:0001257 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE Onset: CHILDHOOD
Show evidence (2 references)
PMID:34765690 SUPPORT Human Clinical
"They developed generalized spasticity with brisk reflexes, but with the absence of clonus."
Documents generalized spasticity in the affected siblings.
PMID:38286424 SUPPORT Human Clinical
"Biallelic variants in PTRHD1 have been associated with autosomal recessive intellectual disability, spasticity, and juvenile parkinsonism, with few reported cases."
Spasticity named as a core element of the established phenotypic spectrum.
Pectus excavatum VERY_RARE HP:0000767 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pectus excavatum (HP:0000767). HP:0000767 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41918506 SUPPORT Human Clinical
"Patients have exotropia and the three patients examined in detail have pectus excavatum and prominent clavicles."
Documents the skeletal findings in a single reported family.
Nervous System 17
Global developmental delay VERY_FREQUENT HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263), qualified as infantile onset. HP:0001263 is a phenotype from the Human Phenotype Ontology.
Onset: INFANTILE
Show evidence (1 reference)
PMID:34765690 SUPPORT Human Clinical
"All cases reported shared a consistent phenotype of delayed developmental milestones and moderate to severe ID. The onset of symptoms was present since late infancy."
All reported cases at the time shared delayed milestones with late-infantile onset, supporting the VERY_FREQUENT band.
Impaired intellectual development VERY_FREQUENT Intellectual disability HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249), qualified as childhood onset. HP:0001249 is a phenotype from the Human Phenotype Ontology.
Onset: CHILDHOOD
Show evidence (2 references)
PMID:38286424 SUPPORT Human Clinical
"Biallelic variants in PTRHD1 have been associated with autosomal recessive intellectual disability, spasticity, and juvenile parkinsonism, with few reported cases."
Intellectual disability is a defining, universally reported feature.
PMID:41918506 SUPPORT Human Clinical
"In all 10 families, onset of ID was early childhood, and in parkinsonism, later childhood to the fourth decade."
Fixes the early-childhood onset of the cognitive phenotype and its separation in time from the motor phenotype in every reported family.
Delayed speech and language development HP:0000750 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed speech and language development (HP:0000750), qualified as childhood onset. HP:0000750 is a phenotype from the Human Phenotype Ontology.
Onset: CHILDHOOD
Show evidence (1 reference)
PMID:41918506 SUPPORT Human Clinical
"Other notable findings are mild developmental delay manifesting with learning disability, language and speech delay, exotropia, pectus excavatum, prominent clavicles, poor social-emotional skills, and inability to communicate"
Documents language and speech delay in the affected siblings.
Attention deficit hyperactivity disorder HP:0007018 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Attention deficit hyperactivity disorder (HP:0007018), qualified as childhood onset. HP:0007018 is a phenotype from the Human Phenotype Ontology.
Onset: CHILDHOOD
Show evidence (2 references)
PMID:34765690 SUPPORT Human Clinical
"subsequently diagnosed with attention deficit hyperactivity disorder"
Formal ADHD diagnosis in a PTRHD1 proband.
PMID:41918506 SUPPORT Human Clinical
"Early onset behavioral problems in presented patients include attention deficit, hyperactivity, aggressive behavior and seclusion, apraxia of speech, stuttering, and somniloquy."
Independent report of early-onset attention deficit and hyperactivity.
Aggressive behavior HP:0000718 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Aggressive behavior (HP:0000718), qualified as childhood onset. HP:0000718 is a phenotype from the Human Phenotype Ontology.
Onset: CHILDHOOD
Show evidence (1 reference)
PMID:41918506 SUPPORT Human Clinical
"are hyperactive, impulsive, and exhibit aggressive behavior"
Reports aggressive behavior in two of four affected siblings of one family, with marked intrafamilial variability. No cross-cohort count is available, so no frequency band is asserted.
Obsessive-compulsive behavior Compulsive behaviors HP:0000722 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Obsessive-compulsive behavior, annotated with Compulsive behaviors (HP:0000722). HP:0000722 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34765690 SUPPORT Human Clinical
"spending hours wiping the floor and washing her hands"
Documents prominent obsessive-compulsive ritual behavior in an affected individual.
Anxiety HP:0000739 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anxiety (HP:0000739). HP:0000739 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34765690 SUPPORT Human Clinical
"Other reported behavioral symptoms reported included depression, anxiety, sleep disturbances, and hypersexuality."
Anxiety listed among the recurrent behavioral symptoms of the disorder.
Parkinsonism FREQUENT HP:0001300 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Parkinsonism (HP:0001300), qualified as course progressive; young adult onset. HP:0001300 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE Onset: YOUNG ADULT
Show evidence (3 references)
PMID:41918506 SUPPORT Human Clinical
"In all 10 families, onset of ID was early childhood, and in parkinsonism, later childhood to the fourth decade."
Defines the onset window of the parkinsonian arm and its temporal separation from the developmental arm.
PMID:34630269 SUPPORT Human Clinical
"Motor signs of Parkinsonism appeared, at 20–30 years of age."
Independent review giving the 20-30 year motor-onset window in the founding families.
PMID:41722179 SUPPORT Human Clinical
"segregating with severe intellectual disability and variably penetrant parkinsonian features"
Notes that the parkinsonian arm is variably penetrant, which is why the band is FREQUENT rather than obligate despite the disease name.
Bradykinesia FREQUENT HP:0002067 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bradykinesia (HP:0002067), qualified as course progressive. HP:0002067 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:41918506 SUPPORT Human Clinical
"Symptoms of parkinsonism such as bradykinesia, tremor, slowness to respond, and gait problems appeared in the fourth decade in all three affected males."
Bradykinesia present in all three affected males of the Pakistani family.
Resting tremor FREQUENT HP:0002322 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Resting tremor (HP:0002322). HP:0002322 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:27753167 SUPPORT Human Clinical
"presented with ID, muscle stiffness, rest and postural tremor, postural instability, gait disturbances, speech difficulties"
Documents rest and postural tremor in the index proband.
Postural instability OCCASIONAL HP:0002172 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Postural instability (HP:0002172). HP:0002172 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:27753167 SUPPORT Human Clinical
"presented with ID, muscle stiffness, rest and postural tremor, postural instability, gait disturbances, speech difficulties"
Postural instability documented in the index proband.
PMID:41918506 REFUTE Human Clinical
"There was no muscle rigidity and postural instability"
Counter-evidence from the Pakistani family, supporting the OCCASIONAL band.
Hyperreflexia FREQUENT HP:0001347 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hyperreflexia (HP:0001347). HP:0001347 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34765690 SUPPORT Human Clinical
"all patients presented initially with global developmental delay during early childhood and onset of pyramidal signs including spasticity and hyperreflexia"
Hyperreflexia documented as part of childhood-onset pyramidal signs.
Dementia OCCASIONAL HP:0000726 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dementia (HP:0000726), qualified as course progressive; young adult onset. HP:0000726 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE Onset: YOUNG ADULT
Show evidence (1 reference)
PMID:41918506 SUPPORT Human Clinical
"Early onset and nonprogressive ID in the four siblings were assessed as mild to moderate whereas signs of parkinsonism such as bradykinesia, resting tremor, slow body movements, gait problems, and dementia were found only in the recent clinical re-evaluation, after the affected siblings reached..."
Directly contrasts the static ID with the fourth-decade emergence of dementia and parkinsonism - the core biphasic observation of this entry.
Gait ataxia VERY_RARE HP:0002066 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Gait ataxia (HP:0002066). HP:0002066 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41918506 SUPPORT Human Clinical
"Gait examination revealed a mildly ataxic gait characterized by impaired balance and coordination, without features of spasticity or hemiparesis."
Documents gait ataxia in one family. The same paper groups it with exotropia and the skeletal findings as features that widen the phenotype beyond the ten previously reported families, so it takes the same VERY_RARE band as those.
Hypersomnia Excessive daytime somnolence HP:0001262 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypersomnia, annotated with Excessive daytime somnolence (HP:0001262). HP:0001262 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:34630269 SUPPORT Human Clinical
"Phenotypes were variably complicated by muscle stiffness, postural tremor, pyramidal signs, sensory-motor polyneuropathy, behavioral disorders, and hypersomnia."
Review names hypersomnia among the variable complications of the PTRHD1 phenotype.
PMID:27753167 SUPPORT Human Clinical
"psychiatric symptoms such as anxiety, hypersomnia, and hypersexuality"
Documents hypersomnia in the index Iranian proband.
Depression HP:0000716 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Depression (HP:0000716). HP:0000716 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34765690 SUPPORT Human Clinical
"Other reported behavioral symptoms reported included depression, anxiety, sleep disturbances, and hypersexuality."
Depression listed among the recurrent behavioral symptoms of the disorder.
Speech apraxia VERY_RARE HP:0011098 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Apraxia of speech, annotated with Speech apraxia (HP:0011098), qualified as childhood onset. HP:0011098 is a phenotype from the Human Phenotype Ontology.
Onset: CHILDHOOD
Show evidence (1 reference)
PMID:41918506 SUPPORT Human Clinical
"Early onset behavioral problems in presented patients include attention deficit, hyperactivity, aggressive behavior and seclusion, apraxia of speech, stuttering, and somniloquy."
Reported in a single family and not described in the ten previously reported families, supporting the VERY_RARE band.
Other 7
Sleep talking HP:0025187 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sleep talking (HP:0025187), qualified as childhood onset. HP:0025187 is a phenotype from the Human Phenotype Ontology.
Onset: CHILDHOOD
Show evidence (1 reference)
PMID:41918506 SUPPORT Human Clinical
"Early onset behavioral problems in presented patients include attention deficit, hyperactivity, aggressive behavior and seclusion, apraxia of speech, stuttering, and somniloquy."
Documents somniloquy among the early behavioral features.
Extensor plantar response FREQUENT Babinski sign HP:0003487 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Babinski sign (HP:0003487). HP:0003487 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34765690 SUPPORT Human Clinical
"these patients developed pyramidal signs consisting of spasticity, hyperreflexia, and upgoing toes"
Reported across the then-published cohort in the same sentence that documents spasticity and hyperreflexia, so it takes the same FREQUENT band as those two.
Generalized-onset seizure VERY_RARE HP:0002197 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Generalized-onset seizure (HP:0002197), qualified as childhood onset. HP:0002197 is a phenotype from the Human Phenotype Ontology.
Onset: CHILDHOOD
Show evidence (1 reference)
PMID:38286424 SUPPORT Human Clinical
"Notably, she developed genetic generalized epilepsy at age 4, persisting into adulthood."
Single-case report of generalized epilepsy; the authors themselves frame it as a potential extension of the spectrum, supporting the VERY_RARE band.
Exotropia VERY_RARE HP:0000577 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Exotropia (HP:0000577). HP:0000577 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41918506 SUPPORT Human Clinical
"Gait ataxia, exotropia, pectus excavatum, and prominent clavicles further widen the clinical phenotype."
Reported in a single family as a phenotype-widening feature, supporting the VERY_RARE band.
Postural tremor HP:0002174 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Postural tremor (HP:0002174). HP:0002174 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:34630269 SUPPORT Human Clinical
"Phenotypes were variably complicated by muscle stiffness, postural tremor, pyramidal signs, sensory-motor polyneuropathy, behavioral disorders, and hypersomnia."
Review names postural tremor among the variable complications of the PTRHD1 phenotype.
PMID:27753167 SUPPORT Human Clinical
"presented with ID, muscle stiffness, rest and postural tremor, postural instability, gait disturbances, speech difficulties"
Documents postural tremor in the index Iranian proband.
Sensorimotor neuropathy HP:0007141 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sensory-motor polyneuropathy, annotated with Sensorimotor neuropathy (HP:0007141). HP:0007141 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34630269 SUPPORT Human Clinical
"Phenotypes were variably complicated by muscle stiffness, postural tremor, pyramidal signs, sensory-motor polyneuropathy, behavioral disorders, and hypersomnia."
The only source for peripheral-nerve involvement in PTRHD1 disease; it is a narrative review listing it as a variable complication, with no counts and no primary electrophysiology, so no frequency band is asserted.
Stuttering VERY_RARE HP:0025268 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Stuttering (HP:0025268), qualified as childhood onset. HP:0025268 is a phenotype from the Human Phenotype Ontology.
Onset: CHILDHOOD
Show evidence (1 reference)
PMID:41918506 SUPPORT Human Clinical
"He stutters, has unclear language, and is hyperactive with recurrent episodes of aggressive behavior."
Documents stuttering in one affected sibling of one family, supporting the VERY_RARE band.
🧬

Genetic Associations

1
PTRHD1
Gene: PTRHD1 hgnc:33782 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PTRHD1 (hgnc:33782). hgnc:33782 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (5 references)
PMID:27753167 SUPPORT Human Clinical
"The chromosome, 2p23.3, was identified as the disease-associated locus, and a homozygous PTRHD1 mutation (c.157C>T) was then established as the disease-causing mutation."
Original gene-disease assignment, mapping the locus to 2p23.3 and establishing PTRHD1 c.157C>T as causal in an Iranian consanguineous family.
PMID:27753167 SUPPORT Human Clinical
"both PTRHD1 mutations identified in families with ID and parkinsonism lie within the PTH2 domain (25-139 amino-acids) of the PTRHD1 protein"
Localizes the disease alleles to the single PTH2 domain of the protein.
PMID:30398675 SUPPORT Human Clinical
"A homozygous 28-nucleotide frameshift deletion in the PTRHD1 coding region was identified in the 3 affected family members and linked to the disease with genome-wide significant evidence."
Independent linkage-supported identification of a truncating allele, establishing loss of function as the mechanism.
+ 2 more references
🔬

Variants

3
PTRHD1 c.169_196del (p.Ala57Argfs*26) Pathogenic
Gene: PTRHD1 hgnc:33782 HUGO Gene Nomenclature Committee (hgnc) Relation: this variant is in this gene This variant is in PTRHD1 (hgnc:33782). hgnc:33782 is a gene from the HUGO Gene Nomenclature Committee.
Recurrent homozygous 28-nucleotide frameshift deletion in PTRHD1 exon 1, reported independently in a South African and an Omani consanguineous family and, per the most recent tally, carried by three families in total. Functional work in patient primary cells showed that the mutant transcript escapes nonsense-mediated decay and that a truncated (~81 amino-acid) but stable protein is expressed, so the allele is not a simple null by transcript degradation.
Show evidence (2 references)
PMID:34765690 SUPPORT Human Clinical
"A homozygous 28-nucleotide frameshift deletion introducing a premature stop codon in the PTRHD1 exon 1 was identified in the four affected members."
Identifies the recurrent frameshift allele in the Omani family.
PMID:34765690 SUPPORT In Vitro
"Real-time PCR showed that mRNA expression of the mutant PTRHD1 is higher compared to the wild-type."
Patient-cell RT-qPCR showing the mutant transcript is not degraded, supporting NMD escape rather than loss of transcript.
PTRHD1 c.155G>A (p.Cys52Tyr) Pathogenic
Gene: PTRHD1 hgnc:33782 HUGO Gene Nomenclature Committee (hgnc) Relation: this variant is in this gene This variant is in PTRHD1 (hgnc:33782). hgnc:33782 is a gene from the HUGO Gene Nomenclature Committee.
Recurrent homozygous missense allele first reported in an Iranian sibling pair and later found in an unrelated Pakistani family with a very late (fourth-decade), atypical parkinsonian phase. Cys52 is conserved across species except C. elegans and lies immediately adjacent to the putative ligand-binding residue His53.
Show evidence (1 reference)
PMID:41918506 SUPPORT Human Clinical
"Linkage analysis using SNP genotyping followed by exome sequencing led to the discovery of PTRHD1 c.155G>A (p.Cys52Tyr), already reported in an Iranian sibling pair."
Confirms recurrence of the p.Cys52Tyr allele in an unrelated kindred.
PTRHD1 c.365G>A (p.Arg122Gln) Pathogenic
Gene: PTRHD1 hgnc:33782 HUGO Gene Nomenclature Committee (hgnc) Relation: this variant is in this gene This variant is in PTRHD1 (hgnc:33782). hgnc:33782 is a gene from the HUGO Gene Nomenclature Committee.
Homozygous missense allele reported in a large kinship comprising three related families and, independently, in an Austrian individual whose phenotype additionally included genetic generalized epilepsy.
Show evidence (1 reference)
PMID:38286424 SUPPORT Human Clinical
"Using diagnostic exome sequencing, we identified a homozygous missense variant (c.365G > A, p.(Arg122Gln)) in PTRHD1 (NM_001013663)."
Documents the p.Arg122Gln allele and its transcript reference.
💊

Medical Actions

3
Levodopa
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: levodopa CHEBI:15765 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses levodopa, annotated with L-dopa (CHEBI:15765). CHEBI:15765 is a therapeutic agent from Chemical Entities of Biological Interest.
A monitored levodopa trial is the principal symptomatic option once parkinsonism becomes functionally limiting. Most reported PTRHD1 patients who developed parkinsonism in the third or fourth decade had levodopa-responsive symptoms, which is also the pharmacological basis for inferring a presynaptic nigrostriatal dopaminergic deficit. Quantitative response rates, durability, and dyskinesia risk have not been reported in this disorder, and at least one patient was unable to cooperate with a levodopa trial.
Mechanism Target:
Striatal Dopamine Deficiency and Basal Ganglia Motor Circuit Dysfunction — Levodopa is decarboxylated to dopamine in surviving nigrostriatal terminals and other striatal cells, restoring striatal dopaminergic tone and correcting basal ganglia motor-circuit imbalance. It does not act on the upstream PTRHD1 lesion or on neuronal loss.
Show evidence (2 references)
PMID:34765690 SUPPORT Human Clinical
"Most of these patients developed levodopa‐responsive parkinsonism symptoms around the third and fourth decade."
Documents levodopa responsiveness in most of the seven patients from the three families reported as of 2021. No quantitative response rate, durability, or dyskinesia-risk data exist for this disorder.
PMID:34765690 SUPPORT Human Clinical
"She was not cooperative for the levodopa trial and OCD treatment."
Illustrates a practical limitation: behavioral and cognitive impairment can prevent a formal levodopa trial, which is part of why response data are sparse.
Genetic Counseling and Cascade Testing
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Because transmission is biallelic and most reported families are consanguineous, genetic counseling for a 25% recurrence risk per pregnancy, carrier testing of at-risk relatives once the familial variant is known, and discussion of prenatal or preimplantation genetic testing are the principal preventive interventions.
Show evidence (1 reference)
PMID:41722179 SUPPORT Human Clinical
"This study expands the mutational and geographical spectrum of PTRHD1-related disorders and reinforces the inclusion of PTRHD1 in genetic screening panels for early-onset parkinsonism, particularly in individuals with intellectual disability and evidence of autosomal recessive inheritance."
Supports genomic testing (and hence counseling and cascade testing) as the actionable pathway in this recessive disorder.
Multidisciplinary Supportive and Rehabilitative Care
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
No disease-modifying therapy exists. Management is symptom-directed and lifelong: special educational placement and behavioral support for the developmental and psychiatric manifestations, speech and language therapy for the marked language delay, physiotherapy and mobility aids for spasticity and later parkinsonian gait impairment, and standard treatment of epilepsy and sleep disturbance where present. Longitudinal movement-disorder surveillance is warranted into adulthood because parkinsonism may emerge decades after the neurodevelopmental diagnosis.
Show evidence (2 references)
PMID:36699000 SUPPORT Human Clinical
"and involvement of a movement disorder specialist may be considered"
Supports the longitudinal movement-disorder surveillance recommended here. It is class-level guidance for genetic neurodevelopmental disorders with parkinsonism (the group that includes PTRHD1); no PTRHD1-specific management study or guideline exists.
PMID:36699000 SUPPORT Human Clinical
"in view of the comorbidity in many GNDs, which may involve clinical experts from many subspecialties in addition to the family doctor and movement disorder specialist"
Supports the multidisciplinary framing of care at the level of the disease class; the individual components recommended here (special education, speech and language therapy, physiotherapy, antiseizure treatment) are standard practice extrapolated from the constituent phenotypes and are not separately evidenced for PTRHD1.
🔬

Diagnosis

2
Biallelic PTRHD1 variant on exome, genome, or movement-disorder panel sequencing
Diagnosis is genomic. There are no consensus clinical criteria and no biochemical or imaging biomarker. Suspicion should be raised by impaired intellectual development with behavioral abnormalities followed by early-onset parkinsonism, particularly with affected siblings or parental consanguinity; confirmation is a biallelic PTRHD1 variant on exome, genome, or a movement-disorder/Parkinson gene panel, with segregation testing in the family. Because the parkinsonian arm can appear decades after the neurodevelopmental one, PTRHD1 belongs on panels used for both indications.
Whole Exome Sequencing NCIT:C101295 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:41722179 SUPPORT Human Clinical
"This study expands the mutational and geographical spectrum of PTRHD1-related disorders and reinforces the inclusion of PTRHD1 in genetic screening panels for early-onset parkinsonism, particularly in individuals with intellectual disability and evidence of autosomal recessive inheritance."
States the indication for PTRHD1 testing and the panel context in which the diagnosis is made.
PMID:38286424 SUPPORT Human Clinical
"Using diagnostic exome sequencing, we identified a homozygous missense variant (c.365G > A, p.(Arg122Gln)) in PTRHD1 (NM_001013663)."
Worked example of the diagnostic route: a homozygous PTRHD1 variant found on diagnostic exome sequencing.
Exclusion of metabolic, structural, and cytogenetic mimics
Because there is no PTRHD1-specific biomarker, the pre-genomic workup is one of exclusion. In the Omani proband an inborn-error-of-metabolism screen, thyroid function, creatine kinase, chromosomal microarray, and brain MRI were all normal - which is the expected pattern and does not argue against the diagnosis.
Laboratory Procedure NCIT:C25294 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:34765690 SUPPORT Human Clinical
"The following investigations were within normal limits and included an inborn error of metabolism screen, thyroid function test, CK level, chromosomal microarray, and a brain magnetic resonance imaging (MRI) examination."
Enumerates the exclusion workup that is normal in PTRHD1 disease.
🩻

Imaging Findings

1
Unremarkable brain MRI
Brain MRI has been grossly normal in reported patients, with no pathognomonic PTRHD1 pattern and no iron accumulation or other neurodegenerative signature described. The one detailed report notes that hippocampal detail could not be reliably assessed on its sequences, so a subtle mesial-temporal abnormality is not formally excluded. This is diagnostically important: a normal MRI does not exclude the diagnosis, and imaging serves mainly to exclude structural and metabolic mimics.
Mri
Show evidence (2 references)
PMID:41918506 SUPPORT Human Clinical
"The results of multiecho and multiplanar brain MRI were grossly unmarkable, but fine detail of hippocampal morphology could not be reliably evaluated due to suboptimal coronal coverage"
Documents a grossly normal brain MRI in four affected siblings, together with the authors' own caveat that hippocampal detail was not reliably assessable.
PMID:34765690 SUPPORT Human Clinical
"The following investigations were within normal limits and included an inborn error of metabolism screen, thyroid function test, CK level, chromosomal microarray, and a brain magnetic resonance imaging (MRI) examination."
Normal MRI plus normal metabolic and chromosomal-microarray workup in an Omani proband, underlining the genomic route to diagnosis.
📈

Progression

2
Phase 1 - static neurodevelopmental phase
Age: Late infancy to childhood
Developmental milestones are delayed from late infancy; motor milestones may be mildly late (one proband sat at 10 months and walked at 20 months) and speech is markedly delayed. This resolves into a stable, NON-progressive impairment of intellectual development with behavioral abnormalities, which can remain the sole presentation for two to four decades. In some families (Omani, South African) childhood pyramidal signs - spasticity and hyperreflexia - accompany this phase and are themselves slowly progressive.
Show evidence (2 references)
PMID:41918506 SUPPORT Human Clinical
"Early onset and nonprogressive ID in the four siblings were assessed as mild to moderate"
Establishes the static character of the first phase.
PMID:34765690 SUPPORT Human Clinical
"All cases reported shared a consistent phenotype of delayed developmental milestones and moderate to severe ID. The onset of symptoms was present since late infancy."
Fixes the late-infantile onset of the first phase.
Phase 2 - progressive motor-neurodegenerative phase
Age: Later childhood to fourth decade (most commonly third to fourth decade)
Progressive parkinsonism (bradykinesia, rest and postural tremor, variable rigidity and postural instability, gait disturbance) emerges after the static phase, frequently accompanied by late cognitive decline/dementia. Onset is variably penetrant and heterogeneous even within a single sibship: in one Omani family only one of four affected siblings had developed parkinsonism by the fourth decade, and in the Pakistani family the eldest sibling was the least affected. Motor features are levodopa-responsive in most reported patients.
Show evidence (3 references)
PMID:41918506 SUPPORT Human Clinical
"In all 10 families, onset of ID was early childhood, and in parkinsonism, later childhood to the fourth decade."
Gives the onset window for the second phase across all reported families.
PMID:34765690 SUPPORT Human Clinical
"Parkinsonism features developed during adulthood."
Confirms adult onset of the motor phase in the Omani family.
PMID:34765690 SUPPORT Human Clinical
"Intrafamilial and disease symptoms heterogeneity were noted, including the onset of parkinsonism symptoms."
Documents the intrafamilial variability in timing of the second phase.
📊

Prevalence

1
Worldwide
Cases In Literature Ultra Rare
Ultra-rare. As of the most recent published tally (2026), ten families had been reported with a homozygous PTRHD1 mutation, all consanguineous and predominantly from the Middle East; the reporting family adds an eleventh. That tally is taken to already include the earlier Austrian singleton (2024); the Italian family (2026) is contemporaneous and may or may not be counted in it. No population prevalence, incidence, or carrier-frequency estimate exists.
Show evidence (2 references)
PMID:41918506 SUPPORT Human Clinical
"To date, ten families have been reported with homozygous PTRHD1 mutation"
Gives the published family count underpinning the ultra-rare classification.
PMID:41918506 SUPPORT Human Clinical
"The majority of the families are from the Middle East, and all have parental consanguinity."
Documents the consanguineous, geographically clustered ascertainment.
🔀

Differential Diagnoses

5

Conditions with similar clinical presentations that must be differentiated from Neurodevelopmental Disorder with Early-Onset Parkinsonism and Behavioral Abnormalities:

Kufor-Rakeb syndrome
Overlapping Features ATP13A2-related autosomal recessive juvenile parkinsonism with pyramidal signs, supranuclear gaze palsy, and cognitive decline - one of the closest clinical mimics of PTRHD1 disease among the atypical juvenile parkinsonisms.
Distinguishing Features
  • Kufor-Rakeb typically shows supranuclear vertical gaze palsy, facial-faucial-finger mini-myoclonus, and often brain iron accumulation on MRI, and its cognitive decline is progressive dementia rather than a static childhood intellectual impairment. Brain MRI in PTRHD1 disease is grossly normal.
Show evidence (3 references)
PMID:27753167 SUPPORT Human Clinical
"Atypical juvenile parkinsonism (AJP) usually refers to a complex form of EOP that is inherited in a recessive manner and manifests with diverse neurological and psychiatric manifestations, including pyramidal signs, abnormalities of eye movements, depression, anxiety, psychosis, impulse control..."
Defines the atypical juvenile parkinsonism class - including the ATP13A2/Kufor-Rakeb prototype with its eye-movement abnormalities - within which PTRHD1 disease must be distinguished.
PMID:27753167 SUPPORT Human Clinical
"To date, pathogenic mutations in at least eight different genes have been reported in AJP."
Establishes the size of the atypical-juvenile-parkinsonism gene panel (ATP13A2, DNAJC6, FBXO7, PLA2G6, SPG11, SPG15, SYNJ1, VPS13C) that must be excluded before attributing disease to PTRHD1.
PMID:34630269 SUPPORT Human Clinical
"VPS13C and PTRHD1 are mutated in families with EOPD complicated by pyramidal signs and cognitive involvement."
Names VPS13C as the closest phenotypic comparator to PTRHD1 within the complicated recessive early-onset parkinsonisms - the two genes share the pyramidal-plus-cognitive complication that separates them from the pure PRKN/PINK1/DJ-1 forms. VPS13C has no dismech entry yet, so it is recorded here rather than as its own differential.
Parkinsonism in other genetic neurodevelopmental disorders
Overlapping Features A broad and growing class in which parkinsonism emerges on a background of a genetic neurodevelopmental disorder - 69 disorders in 422 patients in the most recent systematic review, most frequently 22q11.2 deletion syndrome, beta-propeller protein-associated neurodegeneration, Down syndrome, cerebrotendinous xanthomatosis and Rett syndrome. PTRHD1 is itself one of the entities in this class.
Distinguishing Features
  • Distinction is genomic rather than clinical: the syndromic context (facial dysmorphism, organ involvement, an MRI signature such as brain iron in BPAN, or a biochemical abnormality as in cerebrotendinous xanthomatosis) points to the alternative diagnosis, whereas PTRHD1 disease has a normal MRI, no dysmorphism, and a normal metabolic screen.
Show evidence (1 reference)
PMID:36699000 SUPPORT Human Clinical
"The literature search yielded 208 reports for data-extraction, describing 69 genetic disorders in 422 patients. The five most reported from most to least frequent were: 22q11.2 deletion syndrome, beta-propeller protein-associated neurodegeneration, Down syndrome, cerebrotendinous xanthomatosis,..."
Defines the differential class and its most frequent members.
Parkinson's Disease
Overlapping Features Common, largely sporadic late-onset Parkinson disease. PTRHD1 has not been found to be associated with typical Parkinson disease in European, Chinese and Taiwanese case-control studies; the authors of the European study note that PTRHD1 variants may be either extremely rare in Parkinson disease or not associated at all, and call for larger non-European and family-trio studies.
Distinguishing Features
  • Typical Parkinson disease lacks the preceding childhood neurodevelopmental and behavioral phase and lacks the recessive inheritance pattern; PTRHD1 variants are not enriched in typical Parkinson disease cohorts, so PTRHD1 testing is indicated only in the syndromic, recessive, early-onset context.
Show evidence (3 references)
PMID:34246528 SUPPORT Human Clinical
"Our results show no association between PTRHD1 and PD risk or AAO. We conclude that PTRHD1 does not play a major role in PD in the European population."
Large European case-control and GWAS analysis separating the PTRHD1 syndromic entity from typical Parkinson disease.
PMID:33004232 SUPPORT Human Clinical
"We did not find any pathogenic coding variants or previously reported mutations, suggesting that PTRHD1 mutations are rare in young-onset and familial PD in our population."
Independent negative screen in 464 Taiwanese young-onset/familial PD participants.
PMID:35848037 SUPPORT Human Clinical
"Three rare variants were identified, but rare variants of PTRHD1 were not enriched in PD."
Independent negative burden test in a Chinese case-control cohort (1367 cases, 3298 controls).
{ }

Source YAML

click to show 
name: Neurodevelopmental Disorder with Early-Onset Parkinsonism and Behavioral Abnormalities
creation_date: "2026-08-15T00:00:00Z"
description: >-
  Neurodevelopmental disorder with early-onset parkinsonism and behavioral
  abnormalities (NEDPBA; OMIM 620747) is an ultra-rare autosomal recessive
  condition caused by biallelic loss-of-function variants in PTRHD1
  (peptidyl-tRNA hydrolase domain containing 1) at 2p23.3. Its defining feature
  is a biphasic course in which a single locus appears to bridge
  neurodevelopment and neurodegeneration; the reporting authors put this no more
  strongly than a potential role for the protein in both. In the first phase, delayed developmental milestones become
  apparent in late infancy or early childhood and settle into a static,
  non-progressive impairment of intellectual development with learning
  difficulties, speech and language delay, and prominent behavioral
  abnormalities (attention deficit and hyperactivity, aggression, social
  isolation, obsessive-compulsive behavior, anxiety, and sleep disturbance). In
  the second phase - typically the third or fourth decade, but reported from
  later childhood onward - a progressive motor disorder emerges, combining
  parkinsonism (bradykinesia, rest and postural tremor, rigidity, postural
  instability) with pyramidal signs (spasticity and hyperreflexia); some
  individuals additionally develop dementia, gait ataxia, or generalized
  epilepsy. Parkinsonism has been described as levodopa-responsive in most
  reported patients, and the intrafamilial variability in both the presence and
  the timing of motor features is a consistent finding. Fewer than a dozen
  families have been reported worldwide - from Iran, Oman, Pakistan, South
  Africa, Austria, and Italy, most but not all of them consanguineous - and the
  molecular
  function of PTRHD1 remains genuinely unknown: despite the PTH2 (peptidyl-tRNA
  hydrolase 2) domain that gives the gene its name, the recombinant human
  protein binds tRNA but has no detectable peptidyl-tRNA hydrolase activity. The
  leading (but still unproven) mechanistic hypothesis is that the
  PTH2/ubiquitin-like-domain-binding module links PTRHD1 to the
  ubiquitin-proteasome system, a pathway already implicated in both intellectual
  disability and early-onset parkinsonism.
category: Mendelian
parents:
- Neurodevelopmental Disorder
- Movement Disorder
- Autosomal Recessive Early-Onset Parkinsonism
disease_term:
  preferred_term: neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities
  term:
    id: MONDO:0958323
    label: neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities
synonyms:
- NEDPBA
- PTRHD1-related neurodevelopmental disorder
- PTRHD1-related intellectual disability and parkinsonism
- autosomal recessive intellectual disability with early-onset parkinsonism
- PTRHD1-related juvenile-onset parkinsonism
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
  - classification_value: GENETICS_ENVIRONMENT_DISEASE

notes: >-
  Named-entity-confusion (NEC) preflight. This entity sits in the very
  high-NEC-risk "neurodevelopmental disorder with ..." OMIM series and in the
  crowded early-onset-parkinsonism gene space, so the identity was pinned before
  any deep-research content was used. `uv run runoak -i sqlite:obo:mondo info
  MONDO:0958323 -O obo` returns three identity anchors that all agree:
  `relationship: RO:0004003 HGNC:33782 ! PTRHD1`, `xref: OMIM:620747`, and
  `xref: MEDGEN:1857802`, with `is_a: MONDO:0100500 ! Mendelian
  neurodevelopmental disorder`. Every cited paper was screened to be about
  PTRHD1 and not one of the locus- or phenotype-adjacent early-onset
  parkinsonism genes (PRKN/PARK2, PINK1, PARK7/DJ-1, ATP13A2, SYNJ1, DNAJC6,
  FBXO7, PLA2G6, VPS13C, RAB39B). The ones that already exist as dismech
  entries - PRKN, PARK7 and ATP13A2 (as Kufor-Rakeb syndrome) - are curated
  explicitly under `differential_diagnoses`; the remainder are covered by the
  atypical-juvenile-parkinsonism gene-panel evidence on the Kufor-Rakeb entry,
  which also records VPS13C as the closest phenotypic comparator to PTRHD1. The falcon deep-research report generated for this
  entry was NEC-screened by gene-mention frequency: PTRHD1 42 mentions versus 1
  each for PRKN, PINK1, PARK7, ATP13A2, SYNJ1, DNAJC6 and FBXO7, and 0 for
  ADORA1 - consistent with the intended entity.

  ADORA1 disambiguation (a documented historical misattribution, not a
  competing gene). The first family in which the disease allele was found
  (PMID:27134041, Jaberi et al. 2016, an Iranian kindred with early-onset
  parkinsonism and cognitive dysfunction) nominated ADORA1 p.Gly279Ser as the
  likely cause while also reporting the homozygous PTRHD1 c.155G>A
  (p.Cys52Tyr) allele. Khodadadi et al. (PMID:27753167) subsequently genotyped
  and sequenced ADORA1 in their own family, found no pathogenic ADORA1 variant
  and incomplete homozygosity across the ADORA1 locus, and concluded that
  PTRHD1 is the causative gene in both families. Note that the PTRHD1 c.155G>A
  allele in the 2016 family is documented in Khodadadi's account of it, not in
  the PMID:27134041 abstract, which does not mention PTRHD1 at all. A follow-up
  letter from the original group (PMID:29143421) shifted the attribution toward
  PTRHD1 but did not fully retract ADORA1 - only its title could be verified
  here (the cache body is unavailable), and that title reads "PTRHD1 and
  possibly ADORA1 mutations contribute to Parkinsonism with intellectual
  disability", i.e. ADORA1 is retained as a possible contributor. The same
  p.Cys52Tyr allele has since been found in an unrelated Pakistani family
  (PMID:41918506). On the balance of that evidence ADORA1 is deliberately NOT
  curated as a causal or modifier gene here. PMID:29143421 has no abstract and
  is cited by no evidence item for that reason; it and PMID:27134041 are
  retained in the top-level `references:` block as provenance for this
  disambiguation.

  CENPO disambiguation. Open Targets returns CENPO as a second, weaker
  association for MONDO:0958323 (surfaced in the falcon report). This appears to
  reflect overlapping locus/variant records at 2p23 rather than an
  independently established second cause, and CENPO is deliberately not curated
  as a causal gene.

  GeneReviews baseline. A PubMed search for a GeneReviews chapter
  (`PTRHD1 GeneReviews[All Fields]`) returned no results; there is no
  GeneReviews chapter for PTRHD1-related disease, and none is tagged in
  `references:`. The clinical baseline used instead is the primary case-series
  literature plus two systematic reviews (PMID:34630269, PMID:36699000).

  Sourcing provenance. One deep-research run was performed (falcon, 2026-08-15,
  516 s). It was used only as a lead generator: it surfaced the two review
  articles and the Open Targets/CENPO caveat, but it produced no verbatim
  patient-level quotations (its own report states that "fabricated quotations
  have not been supplied"). All evidence items in this entry were built from
  PMIDs located by direct PubMed E-utilities search on `PTRHD1` (18 hits, all
  triaged), fetched with `just fetch-reference`, and quoted from the cached
  text. No claim rests on deep-research narrative alone.

  Scope note on parkinsonism phenotype terms. Two published families report a
  parkinsonian syndrome that is explicitly atypical: PMID:41918506 documents
  bradykinesia, tremor and dementia in the fourth decade with NO muscle
  rigidity and NO postural instability, plus a mildly ataxic rather than
  parkinsonian gait. Rigidity and postural instability are therefore curated
  with `frequency: OCCASIONAL` and an explicit refuting evidence item rather
  than as obligate features.

references:
- reference: PMID:34630269
  title: "Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings"
- reference: PMID:36699000
  title: "Parkinsonism in Genetic Neurodevelopmental Disorders: A Systematic Review"
- reference: PMID:29143421
  title: "PTRHD1 and possibly ADORA1 mutations contribute to Parkinsonism with intellectual disability"
- reference: PMID:27134041
  title: "Mutation in ADORA1 identified as likely cause of early-onset parkinsonism and cognitive dysfunction"

prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Ultra-rare. As of the most recent published tally (2026), ten families had
    been reported with a homozygous PTRHD1 mutation, all consanguineous and
    predominantly from the Middle East; the reporting family adds an eleventh.
    That tally is taken to already include the earlier Austrian singleton
    (2024); the Italian family (2026) is contemporaneous and may or may not be
    counted in it. No population prevalence, incidence, or carrier-frequency
    estimate exists.
  evidence:
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To date, ten families have been reported with homozygous PTRHD1
      mutation
    explanation: Gives the published family count underpinning the ultra-rare classification.
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The majority of the families are from the Middle East, and all have
      parental consanguinity.
    explanation: Documents the consanguineous, geographically clustered ascertainment.

inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    All reported families carry biallelic (homozygous) PTRHD1 variants that
    segregate with disease in a recessive pattern. Parental consanguinity is
    documented in all ten families in the most recent published tally, and
    ascertainment has been mainly in consanguineous kindreds of Middle Eastern
    or African origin, but consanguinity is not reported for the Austrian
    singleton or the Italian family, so it is characteristic rather than
    universal. Heterozygous carriers, including obligate-carrier parents, are
    unaffected.
  evidence:
  - reference: PMID:30398675
    reference_title: "PTRHD1 Loss-of-function mutation in an african family with juvenile-onset Parkinsonism and intellectual disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Together with the previous reports, we provide conclusive evidence that
      loss-of-function mutations in PTRHD1 cause autosomal-recessive juvenile
      parkinsonism and intellectual disability.
    explanation: >-
      States the autosomal recessive mode of inheritance for PTRHD1
      loss-of-function disease with genome-wide significant linkage support.
  - reference: PMID:41722179
    reference_title: "Early-onset parkinsonism with intellectual disability in an Italian family associated with a PTRHD1 variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutations in PTRHD1 have recently been implicated in autosomal recessive
      neurodevelopmental syndromes characterized by intellectual disability,
      and variably penetrant early-onset parkinsonism, mainly in consanguineous
      families of Middle Eastern or African origin.
    explanation: >-
      Independent confirmation of recessive inheritance and of the variable
      penetrance of the parkinsonian arm.

genetic:
- name: PTRHD1
  gene_term:
    preferred_term: PTRHD1
    term:
      id: hgnc:33782
      label: PTRHD1
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    PTRHD1 (peptidyl-tRNA hydrolase domain containing 1; formerly C2orf79) at
    2p23.3 encodes a 140-amino-acid protein consisting essentially of a single
    PTH2 (peptidyl-tRNA hydrolase 2) domain spanning residues 25-139. All
    reported disease alleles are homozygous and fall within or truncate this
    domain: the missense alleles c.155G>A (p.Cys52Tyr, Iranian and Pakistani
    families), c.157C>T (p.His53Tyr, Iranian family), c.365G>A (p.Arg122Gln, a
    large Middle Eastern kinship and an Austrian individual) and p.Arg122Trp
    (Iranian family); the 28-nucleotide frameshift deletion c.169_196del
    (p.Ala57Argfs*26, South African and Omani families); and the nonsense
    c.213C>A (p.Tyr71*, Italian family). Loss of function is the accepted
    disease mechanism.
  evidence:
  - reference: PMID:27753167
    reference_title: "PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The chromosome, 2p23.3, was identified as the disease-associated locus,
      and a homozygous PTRHD1 mutation (c.157C>T) was then established as the
      disease-causing mutation.
    explanation: >-
      Original gene-disease assignment, mapping the locus to 2p23.3 and
      establishing PTRHD1 c.157C>T as causal in an Iranian consanguineous family.
  - reference: PMID:27753167
    reference_title: "PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      both PTRHD1 mutations identified in families with ID and parkinsonism lie
      within the PTH2 domain (25-139 amino-acids) of the PTRHD1 protein
    explanation: Localizes the disease alleles to the single PTH2 domain of the protein.
  - reference: PMID:30398675
    reference_title: "PTRHD1 Loss-of-function mutation in an african family with juvenile-onset Parkinsonism and intellectual disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A homozygous 28-nucleotide frameshift deletion in the PTRHD1 coding region
      was identified in the 3 affected family members and linked to the disease
      with genome-wide significant evidence.
    explanation: >-
      Independent linkage-supported identification of a truncating allele,
      establishing loss of function as the mechanism.
  - reference: PMID:41722179
    reference_title: "Early-onset parkinsonism with intellectual disability in an Italian family associated with a PTRHD1 variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The analysis revealed a homozygous nonsense variant (c.213C > A,
      p.Tyr71*), segregating with severe intellectual disability and variably
      penetrant parkinsonian features
    explanation: Adds a nonsense allele and extends the geographical spectrum to Europe.
  - reference: PMID:34816696
    reference_title: "The PTRHD1 Mutation in Intellectual Disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A novel homozygous missense mutation (p.Arg122Trp) was detected in the
      PTRHD1 gene.
    explanation: >-
      Adds the p.Arg122Trp allele in an Iranian consanguineous family in whom
      intellectual disability dominated the presentation.

variants:
- name: PTRHD1 c.169_196del (p.Ala57Argfs*26)
  description: >-
    Recurrent homozygous 28-nucleotide frameshift deletion in PTRHD1 exon 1,
    reported independently in a South African and an Omani consanguineous
    family and, per the most recent tally, carried by three families in total. Functional work in patient primary cells showed that the mutant
    transcript escapes nonsense-mediated decay and that a truncated (~81
    amino-acid) but stable protein is expressed, so the allele is not a simple
    null by transcript degradation.
  gene:
    preferred_term: PTRHD1
    term:
      id: hgnc:33782
      label: PTRHD1
  clinical_significance: PATHOGENIC
  evidence:
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A homozygous 28-nucleotide frameshift deletion introducing a premature
      stop codon in the PTRHD1 exon 1 was identified in the four affected
      members.
    explanation: Identifies the recurrent frameshift allele in the Omani family.
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Real-time PCR showed that mRNA expression of the mutant PTRHD1 is higher
      compared to the wild-type.
    explanation: >-
      Patient-cell RT-qPCR showing the mutant transcript is not degraded,
      supporting NMD escape rather than loss of transcript.
- name: PTRHD1 c.155G>A (p.Cys52Tyr)
  description: >-
    Recurrent homozygous missense allele first reported in an Iranian sibling
    pair and later found in an unrelated Pakistani family with a very late
    (fourth-decade), atypical parkinsonian phase. Cys52 is conserved across
    species except C. elegans and lies immediately adjacent to the putative
    ligand-binding residue His53.
  gene:
    preferred_term: PTRHD1
    term:
      id: hgnc:33782
      label: PTRHD1
  clinical_significance: PATHOGENIC
  evidence:
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Linkage analysis using SNP genotyping followed by exome sequencing led to
      the discovery of PTRHD1 c.155G>A (p.Cys52Tyr), already reported in an
      Iranian sibling pair.
    explanation: Confirms recurrence of the p.Cys52Tyr allele in an unrelated kindred.
- name: PTRHD1 c.365G>A (p.Arg122Gln)
  description: >-
    Homozygous missense allele reported in a large kinship comprising three
    related families and, independently, in an Austrian
    individual whose phenotype additionally included genetic generalized
    epilepsy.
  gene:
    preferred_term: PTRHD1
    term:
      id: hgnc:33782
      label: PTRHD1
  clinical_significance: PATHOGENIC
  evidence:
  - reference: PMID:38286424
    reference_title: "A Homozygous PTRHD1 Missense Variant (p.Arg122Gln) in an Individual with Intellectual Disability, Generalized Epilepsy, and Juvenile Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Using diagnostic exome sequencing, we identified a homozygous missense
      variant (c.365G > A, p.(Arg122Gln)) in PTRHD1 (NM_001013663).
    explanation: Documents the p.Arg122Gln allele and its transcript reference.

mechanistic_hypotheses:
- hypothesis_group_id: ptrhd1_ubiquitin_proteasome_model
  hypothesis_label: PTH2/UBL-Domain Link to Ubiquitin-Proteasome System Failure
  status: EMERGING
  description: >-
    The leading - but explicitly unproven - mechanistic model. PTRHD1 consists
    essentially of a PTH2 (peptidyl-tRNA hydrolase 2) domain, and every
    disease-associated allele lies within or truncates it. In yeast, the Pth2
    protein is a ubiquitin-like (UBL) domain-binding protein that participates
    in the ubiquitin-proteasome pathway and retards ubiquitin-mediated
    degradation. Because the ubiquitin-proteasome system is independently
    implicated both in intellectual disability (UBE3A, UBE2A, CUL4B, BRWD3) and
    in early-onset parkinsonism (parkin/PRKN, FBXO7), the proposal is that
    PTRHD1 loss of function degrades proteostasis in a way that impairs brain
    development and later renders vulnerable neuronal populations
    degeneration-prone. The originating authors state this as speculation, no
    disease-specific proteasome assay has been reported in patient neurons, and
    the alternative that PTRHD1 acts in translation-associated RNA quality
    control is not excluded.
  evidence:
  - reference: PMID:27753167
    reference_title: "PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      we speculated that PTRHD1 genetic variability might cause ID and
      parkinsonism through defects in the ubiquitin-proteasome system, as
      observed in other inherited forms of parkinsonism and ID.
    explanation: >-
      The originating statement of the hypothesis, explicitly framed by its
      authors as speculation rather than demonstrated mechanism.
  - reference: PMID:27753167
    reference_title: "PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The PTH2 domain is a ubiquitin-like (UBL) domain-binding protein that is
      known to participate in the ubiquitin-proteasome pathway and has been
      shown to suppress ubiquitin-mediated degradation.
    explanation: >-
      Provides the domain-level biochemical rationale (from yeast Pth2) that
      motivates the hypothesis; it is homology-based, not PTRHD1-specific.
  - reference: PMID:34630269
    reference_title: "Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Intriguingly, the pathogenic variants causing Parkinsonism are in the
      ubiquitin-like (UBL) domain-binding site of the protein.
    explanation: >-
      Independent review notes that the disease alleles cluster in the
      UBL-domain-binding site, the structural argument for the hypothesis.
  - reference: PMID:27235175
    reference_title: "Expression, purification, and buffer solubility optimization of the putative human peptidyl-tRNA hydrolase PTRHD1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Additionally, we report binding to tRNA but absence of peptidyl-tRNA
      hydrolase activity. Thus, PTRHD1 is not a Pth and the functional
      consequence of nucleotide binding remains undefined.
    explanation: >-
      Constrains the hypothesis space from the other direction: the domain's
      nominal enzymatic activity is absent in the recombinant human protein, so
      the disease mechanism cannot simply be loss of peptidyl-tRNA hydrolysis.

pathophysiology:
- name: PTRHD1 Biallelic Loss of Function
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    Homozygous missense, frameshift, or nonsense variants in the single PTH2
    domain of PTRHD1 (2p23.3) abolish or corrupt the function of the
    140-amino-acid protein. Linkage-supported segregation in multiple unrelated
    consanguineous families, absence of the alleles from ethnically matched
    control chromosomes and population databases, and the presence of clearly
    truncating alleles together establish loss of function as the disease
    mechanism. PTRHD1 is widely expressed, including throughout the adult brain
    (cortex, cerebellum, brainstem, substantia nigra, pons, putamen, and spinal
    cord), which is consistent with a phenotype that spans cognitive,
    behavioral, pyramidal, and extrapyramidal domains.
  gene:
    preferred_term: PTRHD1
    term:
      id: hgnc:33782
      label: PTRHD1
  evidence:
  - reference: PMID:30398675
    reference_title: "PTRHD1 Loss-of-function mutation in an african family with juvenile-onset Parkinsonism and intellectual disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Together with the previous reports, we provide conclusive evidence that
      loss-of-function mutations in PTRHD1 cause autosomal-recessive juvenile
      parkinsonism and intellectual disability.
    explanation: Establishes biallelic loss of function as the causal molecular lesion.
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      PTRHD1 is expressed in many organs, and we found widespread expression in
      the adult brain.
    explanation: >-
      Expression data supporting a broadly distributed CNS substrate for the
      loss-of-function lesion.
  downstream:
  - target: Escape of Nonsense-Mediated Decay with Stable Truncated Protein
    causal_link_type: DIRECT
    description: >-
      Truncating PTRHD1 alleles do not simply eliminate the transcript; the
      mutant mRNA is stable and a shortened protein is produced.
  - target: Impaired Ubiquitin-Proteasome Protein Quality Control
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - ptrhd1_ubiquitin_proteasome_model
    description: >-
      Hypothesized link, based on the UBL-domain-binding activity of the PTH2
      domain family; not demonstrated in patient neurons.
  - target: Disrupted Development of Cognitive and Behavioral Circuits
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The first, static phase of the biphasic course: developmental milestones
      are delayed from late infancy and cognitive/behavioral impairment is then
      non-progressive.
  - target: Nigrostriatal Dopaminergic Neuron Degeneration
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The second, progressive phase, emerging years to decades after the
      developmental phase in the same individuals.
  - target: Corticospinal Tract Dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Pyramidal involvement, present in some families from childhood alongside
      the developmental phase and progressive in others.
  - target: Gait ataxia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
        Reported as mildly ataxic and explicitly NOT parkinsonian and NOT spastic, so
        it is not placed on either curated motor arm. The reporting authors suggest
        cerebellar or cerebellar-network involvement; no such node is curated because
        there is no imaging or pathological evidence for it.
  - target: Sensorimotor neuropathy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
        Peripheral-nerve involvement lies outside both the nigrostriatal and the
        corticospinal arms and has no curated mechanism; it is attached to the root
        lesion to record that it is unexplained.
  - target: Hypersomnia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
        Excessive sleepiness is reported alongside the motor and behavioral features
        but cannot be assigned to a specific curated arm.
  - target: Generalized-onset seizure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
        Single-case epilepsy, proposed as a spectrum extension; no epileptogenic
        mechanism is curated for PTRHD1.
  - target: Exotropia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
        Single-family finding with no curated mechanism.
  - target: Pectus excavatum
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
        Single-family skeletal finding with no curated mechanism; PTRHD1 is widely
        expressed outside the nervous system, but no connection has been shown.

- name: Escape of Nonsense-Mediated Decay with Stable Truncated Protein
  biological_scale: MOLECULAR
  mechanism_confidence: ESTABLISHED
  description: >-
    Functional work on the recurrent c.169_196del (p.Ala57Argfs*26) allele in
    primary cells from four affected members of an Omani family showed that,
    contrary to in-silico prediction, the premature-termination-codon transcript
    escapes nonsense-mediated mRNA decay and is in fact expressed at higher
    levels than wild type. Immunoblot and isoelectric focusing detected a stable
    truncated protein of roughly 8-9 kDa (isoelectric point ~11) instead of the
    15 kDa wild-type product. The disease allele therefore produces an abnormal
    protein species rather than protein absence, which leaves open whether the
    pathogenic effect is pure loss of function or includes an aberrant activity
    of the truncated product.
  evidence:
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We further confirmed the apparent transcript escape of the
      nonsense-mediated messenger RNA (mRNA) decay pathway.
    explanation: Direct patient-cell demonstration of NMD escape.
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Western blotting and isoelectric focusing identified a truncated, but
      stable mutant PTRHD1 protein expressed in the patient
    explanation: >-
      Shows the truncated protein is stably expressed in patient primary cells,
      so the allele is not a protein-null.

- name: Impaired Ubiquitin-Proteasome Protein Quality Control
  biological_scale: MOLECULAR
  mechanism_confidence: HYPOTHETICAL
  description: >-
    Hypothesized proximal consequence of PTRHD1 loss of function. The PTH2
    domain family binds ubiquitin-like (UBL) domains and participates in the
    ubiquitin-proteasome pathway, and all reported disease alleles fall within
    that domain - although since PTH2 spans residues 25-139 of a 140-amino-acid
    protein, that localization is a weak constraint. A secondary review adds
    that the parkinsonism-causing variants sit in the UBL-domain-binding site,
    but it was written before p.Arg122Gln, p.Arg122Trp and p.Tyr71* were
    reported and so cannot speak to the full allele set. Disturbed
    ubiquitin-dependent proteolysis would plausibly account for the double
    phenotype, since the ubiquitin-proteasome system is required for brain
    development, synaptic plasticity, and long-term memory formation, and its
    failure is a recognized route to both intellectual disability and
    early-onset parkinsonism. No proteasome-activity or polyubiquitinated-protein
    measurement has been reported in PTRHD1-deficient human neurons, so this node
    remains a hypothesis rather than a demonstrated step.
  biological_processes:
  - preferred_term: proteasome-mediated ubiquitin-dependent protein catabolic process
    term:
      id: GO:0043161
      label: proteasome-mediated ubiquitin-dependent protein catabolic process
    modifier: DECREASED
  - preferred_term: ubiquitin-dependent protein catabolic process
    term:
      id: GO:0006511
      label: ubiquitin-dependent protein catabolic process
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:27753167
    reference_title: "PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      the role that the ubiquitin proteasome system plays in brain development,
      synaptic plasticity, and long-term memory formation
    explanation: >-
      States the biological rationale linking a UPS defect to the
      neurodevelopmental arm of the phenotype; not PTRHD1-specific experimental
      evidence.
  - reference: PMID:36699000
    reference_title: "Parkinsonism in Genetic Neurodevelopmental Disorders: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Proposed disease mechanisms included aberrant mitochondrial function and
      disruptions in neurotransmitter metabolism, endosomal trafficking, and the
      autophagic-lysosomal and ubiquitin-proteasome system.
    explanation: >-
      Places ubiquitin-proteasome failure among the recurrent proposed
      mechanisms across genetic neurodevelopmental disorders with parkinsonism,
      the disease class to which this entry belongs.
  downstream:
  - target: Disrupted Development of Cognitive and Behavioral Circuits
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - ptrhd1_ubiquitin_proteasome_model
  - target: Nigrostriatal Dopaminergic Neuron Degeneration
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - ptrhd1_ubiquitin_proteasome_model

- name: Disrupted Development of Cognitive and Behavioral Circuits
  biological_scale: TISSUE
  mechanism_confidence: PROVISIONAL
  description: >-
    The first arm of the biphasic course. Loss of PTRHD1 during brain
    development produces delayed milestones from late infancy, mild to severe
    impairment of intellectual development, speech and language delay, and a
    characteristic behavioral profile (attention deficit and hyperactivity,
    impulsivity, aggression, social isolation, obsessive-compulsive behavior,
    anxiety, and sleep disturbance). Critically, this arm is STATIC: cognitive
    impairment in the best-followed family was explicitly described as
    early-onset and non-progressive, in contrast to the later motor arm. Brain
    MRI is grossly unremarkable, so the substrate is presumed to be circuit- and
    synapse-level rather than a gross malformation.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: nervous system development
    term:
      id: GO:0007399
      label: nervous system development
    modifier: ABNORMAL
  evidence:
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All cases reported shared a consistent phenotype of delayed developmental
      milestones and moderate to severe ID. The onset of symptoms was present
      since late infancy.
    explanation: >-
      Establishes the late-infantile onset of the developmental arm across all
      then-reported cases.
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early onset and nonprogressive ID in the four siblings were assessed as
      mild to moderate
    explanation: >-
      Key evidence that the cognitive arm is static rather than progressive -
      the feature that makes this a true neurodevelopment-to-neurodegeneration
      bridge rather than a single progressive dementia.
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The behavioral symptoms range from hyperactivity, aggressive behavior,
      attention deficit, social isolation, and somniloquy (sleep-talking).
    explanation: Characterizes the behavioral-abnormality arm named in the disease label.
  downstream:
  - target: Global developmental delay
    causal_link_type: DIRECT
    description: >-
        Delayed attainment of motor, speech and social milestones is the earliest
        clinical expression of the disrupted developmental program.
  - target: Impaired intellectual development
    causal_link_type: DIRECT
    description: >-
        The cognitive outcome of the developmental arm, static once established.
  - target: Delayed speech and language development
    causal_link_type: DIRECT
    description: >-
        Language is disproportionately affected within the developmental arm.
  - target: Speech apraxia
    causal_link_type: DIRECT
    description: >-
        Motor-speech programming failure reported within the language phenotype.
  - target: Stuttering
    causal_link_type: DIRECT
    description: >-
        Dysfluency reported in the most severely affected sibling of one family.
  - target: Attention deficit hyperactivity disorder
    causal_link_type: DIRECT
    description: >-
        The attention and hyperactivity component of the behavioral arm.
  - target: Aggressive behavior
    causal_link_type: DIRECT
    description: >-
        Externalizing behavior reported in a subset of affected siblings.
  - target: Obsessive-compulsive behavior
    causal_link_type: DIRECT
    description: >-
        Compulsive rituals reported in one affected adult.
  - target: Anxiety
    causal_link_type: DIRECT
    description: >-
        Internalizing symptom reported among the recurrent behavioral features.
  - target: Depression
    causal_link_type: DIRECT
    description: >-
        Internalizing symptom reported among the recurrent behavioral features.
  - target: Sleep talking
    causal_link_type: DIRECT
    description: >-
        Sleep-related behavioral symptom reported in one family.

- name: Nigrostriatal Dopaminergic Neuron Degeneration
  biological_scale: CELLULAR
  mechanism_confidence: HYPOTHETICAL
  conforms_to: "parkinsonism_dopaminergic_degeneration#Nigrostriatal Dopaminergic Neurodegeneration"
  description: >-
    Inferred second arm of the biphasic course. Years to decades after the
    static developmental phase, affected individuals develop progressive
    parkinsonism that in most reported patients has been levodopa-responsive,
    implying a presynaptic nigrostriatal dopaminergic deficit. PTRHD1 is
    expressed in the substantia nigra, striatum, and putamen, providing an
    anatomical substrate. This node is nonetheless marked HYPOTHETICAL and is a
    declared knowledge gap: no neuropathology has ever been reported for a
    PTRHD1 patient, and no dopamine-transporter (DaT-SPECT) imaging result has
    been published - the Omani proband with parkinsonism explicitly had no
    DaTscan available. Conformance to the shared
    parkinsonism_dopaminergic_degeneration module is therefore asserted on
    pharmacological and expression grounds, not on direct demonstration of
    nigral cell loss in this disease.
  cell_types:
  - preferred_term: midbrain dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  locations:
  - preferred_term: substantia nigra pars compacta
    term:
      id: UBERON:0001965
      label: substantia nigra pars compacta
  evidence:
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most of these patients developed levodopa‐responsive parkinsonism symptoms
      around the third and fourth decade.
    explanation: >-
      Reported for most of the seven patients in the three families known as of
      2021. Levodopa responsiveness is indirect evidence of a presynaptic
      nigrostriatal dopaminergic deficit with preserved postsynaptic striatal
      targets; it does not itself demonstrate neuronal loss.
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We found expression of PTRHD1 in different brain parts including the
      striatum and putamen, which are involved in degenerative neurological
      disorders.
    explanation: >-
      Expression in the relevant basal-ganglia structures supports, but does not
      prove, a nigrostriatal locus of degeneration.
  - reference: PMID:36699000
    reference_title: "Parkinsonism in Genetic Neurodevelopmental Disorders: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Results of dopaminergic imaging and response to antiparkinsonian
      medication often supported the neurodegenerative nature of parkinsonism.
    explanation: >-
      Class-level evidence that in genetic neurodevelopmental disorders with
      parkinsonism (a group that explicitly includes PTRHD1) the motor arm is
      generally neurodegenerative rather than developmental; PTRHD1-specific
      imaging and neuropathology are still absent.
  downstream:
  - target: Striatal Dopamine Deficiency and Basal Ganglia Motor Circuit Dysfunction
    causal_link_type: DIRECT
  - target: Dementia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Late cognitive decline appears in the same decade as the motor features,
      superimposed on the static developmental impairment. It is placed on the
      degenerative arm because of that temporal coupling; its anatomical
      substrate has never been examined in this disorder, so the intermediates
      are unknown.

- name: Striatal Dopamine Deficiency and Basal Ganglia Motor Circuit Dysfunction
  biological_scale: TISSUE
  mechanism_confidence: PROVISIONAL
  conforms_to: "parkinsonism_dopaminergic_degeneration#Striatal Dopamine Deficiency and Basal Ganglia Circuit Dysfunction"
  description: >-
    Loss of nigrostriatal dopaminergic input unbalances the basal ganglia motor
    circuit, producing the clinical parkinsonian syndrome: bradykinesia with
    rest and postural tremor, muscle stiffness/rigidity, postural instability,
    and gait disturbance. The syndrome is levodopa-responsive in most reported
    patients, consistent with a dopamine-replaceable striatal deficit. It is
    also atypical in an important minority: one family developed bradykinesia,
    tremor and dementia in the fourth decade with neither muscle rigidity nor
    postural instability, and with a mildly ataxic rather than parkinsonian
    gait, widening the syndrome beyond pure parkinsonism.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  biological_processes:
  - preferred_term: dopamine secretion
    term:
      id: GO:0014046
      label: dopamine secretion
    modifier: DECREASED
  evidence:
  - reference: PMID:27753167
    reference_title: "PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      presented with ID, muscle stiffness, rest and postural tremor, postural
      instability, gait disturbances, speech difficulties, as well as
      psychiatric symptoms such as anxiety, hypersomnia, and hypersexuality.
    explanation: >-
      Documents the full parkinsonian motor syndrome (stiffness, rest and
      postural tremor, postural instability, gait disturbance) in the index
      family.
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There was no muscle rigidity and postural instability, but there were
      unusual features of exotropia, pectus excavatum, and prominent clavicles.
    explanation: >-
      Counter-evidence delimiting the syndrome: in the Pakistani family the
      cardinal signs of rigidity and postural instability were absent even in
      the eldest affected sibling, so these are not obligate features.
  downstream:
  - target: Parkinsonism
    causal_link_type: DIRECT
    description: >-
        The clinical syndrome produced by the striatal dopamine deficit.
  - target: Bradykinesia
    causal_link_type: DIRECT
    description: >-
        The cardinal sign, required for the parkinsonism diagnosis in the reported
        families.
  - target: Resting tremor
    causal_link_type: DIRECT
    description: >-
        Rest tremor as part of the parkinsonian syndrome.
  - target: Postural tremor
    causal_link_type: DIRECT
    description: >-
        Postural tremor as part of the parkinsonian syndrome.
  - target: Rigidity
    causal_link_type: DIRECT
    description: >-
        Increased tone, present in some families and explicitly absent in others.
  - target: Postural instability
    causal_link_type: DIRECT
    description: >-
        Loss of postural reflexes, present in some families and explicitly absent in
        others.

- name: Corticospinal Tract Dysfunction
  biological_scale: TISSUE
  mechanism_confidence: PROVISIONAL
  description: >-
    A pyramidal arm that is separable from the parkinsonian arm and, in some
    families, precedes it by decades. Affected individuals in the South African
    and Omani kindreds developed generalized spasticity, brisk reflexes and
    upgoing toes in childhood, alongside the developmental phase; in the most
    severely affected individual this worsened over time to loss of independent
    ambulation. Notably, the pyramidal arm is not universal - the Pakistani
    family had a mildly ataxic gait explicitly without spasticity or hemiparesis
    - so spasticity is a frequent but not obligate feature.
  locations:
  - preferred_term: corticospinal tract
    term:
      id: UBERON:0002707
      label: corticospinal tract
  evidence:
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      all patients presented initially with global developmental delay during
      early childhood and onset of pyramidal signs including spasticity and
      hyperreflexia
    explanation: >-
      Establishes childhood-onset pyramidal involvement co-occurring with the
      developmental phase, before parkinsonism.
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      these patients developed pyramidal signs consisting of spasticity,
      hyperreflexia, and upgoing toes
    explanation: Enumerates the pyramidal signs across the then-reported cohort.
  downstream:
  - target: Spasticity
    causal_link_type: DIRECT
    description: >-
        Velocity-dependent hypertonia from loss of corticospinal inhibition.
  - target: Hyperreflexia
    causal_link_type: DIRECT
    description: >-
        Brisk deep tendon reflexes from the same upper-motor-neuron lesion.
  - target: Extensor plantar response
    causal_link_type: DIRECT
    description: >-
        Upgoing toes completing the pyramidal picture.

phenotypes:
- category: Neurologic
  name: Global developmental delay
  description: >-
    Delayed attainment of motor, speech, and social milestones, apparent from
    late infancy or early childhood and preceding any motor-neurodegenerative
    feature by years to decades.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
    onset:
      onset_category: INFANTILE
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All cases reported shared a consistent phenotype of delayed developmental
      milestones and moderate to severe ID. The onset of symptoms was present
      since late infancy.
    explanation: >-
      All reported cases at the time shared delayed milestones with
      late-infantile onset, supporting the VERY_FREQUENT band.

- category: Neurologic
  name: Impaired intellectual development
  description: >-
    Impairment of intellectual development with learning difficulties, ranging
    from mild to severe across families and even between siblings. In the
    best-followed kindred the cognitive impairment was explicitly
    non-progressive over nine years of longitudinal follow-up into the fifth
    decade.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
    onset:
      onset_category: CHILDHOOD
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:38286424
    reference_title: "A Homozygous PTRHD1 Missense Variant (p.Arg122Gln) in an Individual with Intellectual Disability, Generalized Epilepsy, and Juvenile Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Biallelic variants in PTRHD1 have been associated with autosomal recessive
      intellectual disability, spasticity, and juvenile parkinsonism, with few
      reported cases.
    explanation: Intellectual disability is a defining, universally reported feature.
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In all 10 families, onset of ID was early childhood, and in parkinsonism,
      later childhood to the fourth decade.
    explanation: >-
      Fixes the early-childhood onset of the cognitive phenotype and its
      separation in time from the motor phenotype in every reported family.

- category: Neurologic
  name: Delayed speech and language development
  description: >-
    Language and speech delay, with poor communication skills persisting into
    adulthood; one reported individual had fewer than 100 words at age 7, and
    apraxia of speech and stuttering have been described.
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
    onset:
      onset_category: CHILDHOOD
  evidence:
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other notable findings are mild developmental delay manifesting with
      learning disability, language and speech delay, exotropia, pectus
      excavatum, prominent clavicles, poor social-emotional skills, and
      inability to communicate
    explanation: Documents language and speech delay in the affected siblings.

- category: Psychiatric
  name: Attention deficit hyperactivity disorder
  description: >-
    Attention deficit with hyperactivity and impulsivity, one of the behavioral
    abnormalities named in the disease label. Formally diagnosed as ADHD in an
    Omani proband and described as attention deficit plus hyperactivity in the
    Pakistani family.
  phenotype_term:
    preferred_term: Attention deficit hyperactivity disorder
    term:
      id: HP:0007018
      label: Attention deficit hyperactivity disorder
    onset:
      onset_category: CHILDHOOD
  evidence:
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      subsequently diagnosed with attention deficit hyperactivity disorder
    explanation: Formal ADHD diagnosis in a PTRHD1 proband.
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early onset behavioral problems in presented patients include attention
      deficit, hyperactivity, aggressive behavior and seclusion, apraxia of
      speech, stuttering, and somniloquy.
    explanation: Independent report of early-onset attention deficit and hyperactivity.

- category: Psychiatric
  name: Aggressive behavior
  description: >-
    Recurrent episodes of aggressive behavior, reported alongside hyperactivity
    and impulsivity in affected male siblings.
  phenotype_term:
    preferred_term: Aggressive behavior
    term:
      id: HP:0000718
      label: Aggressive behavior
    onset:
      onset_category: CHILDHOOD
  evidence:
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      are hyperactive, impulsive, and exhibit aggressive behavior
    explanation: >-
      Reports aggressive behavior in two of four affected siblings of one
      family, with marked intrafamilial variability. No cross-cohort count is
      available, so no frequency band is asserted.

- category: Psychiatric
  name: Obsessive-compulsive behavior
  description: >-
    Prominent obsessive-compulsive disorder was documented in an Omani patient
    who also had parkinsonism, spending hours on repetitive cleaning and
    hand-washing rituals, with associated sleep-onset insomnia.
  phenotype_term:
    preferred_term: Obsessive-compulsive behavior
    term:
      id: HP:0000722
      label: Compulsive behaviors
  evidence:
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      spending hours wiping the floor and washing her hands
    explanation: >-
      Documents prominent obsessive-compulsive ritual behavior in an affected
      individual.

- category: Psychiatric
  name: Anxiety
  description: >-
    Anxiety was among the psychiatric manifestations of the proband of the
    Iranian p.His53Tyr family and is listed among the recurrent behavioral
    symptoms across reported PTRHD1 families.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other reported behavioral symptoms reported included depression, anxiety,
      sleep disturbances, and hypersexuality.
    explanation: Anxiety listed among the recurrent behavioral symptoms of the disorder.

- category: Psychiatric
  name: Sleep talking
  description: >-
    Somniloquy (sleep-talking) was reported as one of the early-onset behavioral
    problems in the Pakistani family.
  phenotype_term:
    preferred_term: Sleep talking
    term:
      id: HP:0025187
      label: Sleep talking
    onset:
      onset_category: CHILDHOOD
  evidence:
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early onset behavioral problems in presented patients include attention
      deficit, hyperactivity, aggressive behavior and seclusion, apraxia of
      speech, stuttering, and somniloquy.
    explanation: Documents somniloquy among the early behavioral features.

- category: Neurologic
  name: Parkinsonism
  description: >-
    Progressive parkinsonism developing after the static developmental phase.
    Across reported families, onset spans later childhood to the fourth decade,
    with most published motor onsets in the third and fourth decades. It is the
    second arm of the biphasic course and is variably penetrant within families.
  phenotype_term:
    preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
    clinical_course: PROGRESSIVE
    onset:
      onset_category: YOUNG_ADULT
  frequency: FREQUENT
  evidence:
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In all 10 families, onset of ID was early childhood, and in parkinsonism,
      later childhood to the fourth decade.
    explanation: >-
      Defines the onset window of the parkinsonian arm and its temporal
      separation from the developmental arm.
  - reference: PMID:34630269
    reference_title: "Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Motor signs of Parkinsonism appeared, at 20–30 years of age.
    explanation: >-
      Independent review giving the 20-30 year motor-onset window in the
      founding families.
  - reference: PMID:41722179
    reference_title: "Early-onset parkinsonism with intellectual disability in an Italian family associated with a PTRHD1 variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      segregating with severe intellectual disability and variably penetrant
      parkinsonian features
    explanation: >-
      Notes that the parkinsonian arm is variably penetrant, which is why the
      band is FREQUENT rather than obligate despite the disease name.

- category: Neurologic
  name: Bradykinesia
  description: >-
    Slowness of voluntary movement, the cardinal parkinsonian sign required for
    the diagnosis in reported families and graded on the UPDRS in the Omani
    patient with parkinsonism.
  phenotype_term:
    preferred_term: Bradykinesia
    term:
      id: HP:0002067
      label: Bradykinesia
    clinical_course: PROGRESSIVE
  frequency: FREQUENT
  evidence:
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Symptoms of parkinsonism such as bradykinesia, tremor, slowness to
      respond, and gait problems appeared in the fourth decade in all three
      affected males.
    explanation: Bradykinesia present in all three affected males of the Pakistani family.

- category: Neurologic
  name: Resting tremor
  description: >-
    Rest tremor was documented in the proband of the index Iranian p.His53Tyr
    family, and tremor was one of the fourth-decade parkinsonian signs in the
    Pakistani family. Postural tremor is curated separately.
  phenotype_term:
    preferred_term: Resting tremor
    term:
      id: HP:0002322
      label: Resting tremor
  frequency: FREQUENT
  evidence:
  - reference: PMID:27753167
    reference_title: "PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      presented with ID, muscle stiffness, rest and postural tremor, postural
      instability, gait disturbances, speech difficulties
    explanation: Documents rest and postural tremor in the index proband.

- category: Neurologic
  name: Rigidity
  description: >-
    Muscle stiffness/rigidity was present in the index Iranian family and graded
    on the UPDRS in an Omani patient, but was explicitly ABSENT in all affected
    members of the Pakistani family even at age 48, so it is not an obligate
    feature.
  phenotype_term:
    preferred_term: Rigidity
    term:
      id: HP:0002063
      label: Rigidity
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:34630269
    reference_title: "Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Phenotypes were variably complicated by muscle stiffness, postural tremor,
      pyramidal signs, sensory-motor polyneuropathy, behavioral disorders, and
      hypersomnia.
    explanation: >-
      Review lists muscle stiffness among the variable complications, i.e. not
      universal.
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A hallmark of muscle rigidity, postural instability for parkinsonism did
      not develop even in the eldest patient aged 48 years.
    explanation: >-
      Explicit counter-evidence: rigidity was absent in an entire family,
      justifying the OCCASIONAL rather than FREQUENT band.

- category: Neurologic
  name: Postural instability
  description: >-
    Impaired postural reflexes with a tendency to fall. Present in the index
    Iranian proband but explicitly absent in the Pakistani and Omani patients
    with parkinsonism.
  phenotype_term:
    preferred_term: Postural instability
    term:
      id: HP:0002172
      label: Postural instability
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:27753167
    reference_title: "PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      presented with ID, muscle stiffness, rest and postural tremor, postural
      instability, gait disturbances, speech difficulties
    explanation: Postural instability documented in the index proband.
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There was no muscle rigidity and postural instability
    explanation: Counter-evidence from the Pakistani family, supporting the OCCASIONAL band.

- category: Neurologic
  name: Spasticity
  description: >-
    Generalized spasticity with brisk reflexes, developing in childhood
    alongside the developmental phase in the Omani and South African kindreds
    and worsening over time to loss of independent ambulation in the most
    severely affected individual. Absent in the Pakistani family.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
    clinical_course: PROGRESSIVE
    onset:
      onset_category: CHILDHOOD
  frequency: FREQUENT
  evidence:
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They developed generalized spasticity with brisk reflexes, but with the
      absence of clonus.
    explanation: Documents generalized spasticity in the affected siblings.
  - reference: PMID:38286424
    reference_title: "A Homozygous PTRHD1 Missense Variant (p.Arg122Gln) in an Individual with Intellectual Disability, Generalized Epilepsy, and Juvenile Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Biallelic variants in PTRHD1 have been associated with autosomal recessive
      intellectual disability, spasticity, and juvenile parkinsonism, with few
      reported cases.
    explanation: Spasticity named as a core element of the established phenotypic spectrum.

- category: Neurologic
  name: Hyperreflexia
  description: >-
    Brisk deep tendon reflexes accompanying the spasticity, part of the pyramidal
    arm of the phenotype.
  phenotype_term:
    preferred_term: Hyperreflexia
    term:
      id: HP:0001347
      label: Hyperreflexia
  frequency: FREQUENT
  evidence:
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      all patients presented initially with global developmental delay during
      early childhood and onset of pyramidal signs including spasticity and
      hyperreflexia
    explanation: Hyperreflexia documented as part of childhood-onset pyramidal signs.

- category: Neurologic
  name: Extensor plantar response
  description: >-
    Upgoing toes (Babinski sign), completing the pyramidal picture in the
    reported cohorts.
  phenotype_term:
    preferred_term: Babinski sign
    term:
      id: HP:0003487
      label: Babinski sign
  frequency: FREQUENT
  evidence:
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      these patients developed pyramidal signs consisting of spasticity,
      hyperreflexia, and upgoing toes
    explanation: >-
      Reported across the then-published cohort in the same sentence that
      documents spasticity and hyperreflexia, so it takes the same FREQUENT
      band as those two.

- category: Neurologic
  name: Dementia
  description: >-
    Late cognitive decline superimposed on the static developmental impairment,
    appearing in the fourth decade together with the parkinsonian features. Its
    emergence marks the transition of the entry from a purely neurodevelopmental
    to a neurodegenerative phenotype.
  phenotype_term:
    preferred_term: Dementia
    term:
      id: HP:0000726
      label: Dementia
    clinical_course: PROGRESSIVE
    onset:
      onset_category: YOUNG_ADULT
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early onset and nonprogressive ID in the four siblings were assessed as
      mild to moderate whereas signs of parkinsonism such as bradykinesia,
      resting tremor, slow body movements, gait problems, and dementia were
      found only in the recent clinical re-evaluation, after the affected
      siblings reached their fourth decade.
    explanation: >-
      Directly contrasts the static ID with the fourth-decade emergence of
      dementia and parkinsonism - the core biphasic observation of this entry.

- category: Neurologic
  name: Gait ataxia
  description: >-
    Mildly ataxic gait with impaired balance and coordination, without
    spasticity or hemiparesis, reported in the Pakistani family. Its presence
    suggests the neurological phenotype may extend beyond pure parkinsonism to
    involve cerebellar networks.
  phenotype_term:
    preferred_term: Gait ataxia
    term:
      id: HP:0002066
      label: Gait ataxia
  frequency: VERY_RARE
  evidence:
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Gait examination revealed a mildly ataxic gait characterized by impaired
      balance and coordination, without features of spasticity or hemiparesis.
    explanation: >-
      Documents gait ataxia in one family. The same paper groups it with
      exotropia and the skeletal findings as features that widen the phenotype
      beyond the ten previously reported families, so it takes the same
      VERY_RARE band as those.

- category: Neurologic
  name: Generalized-onset seizure
  description: >-
    Genetic generalized epilepsy with onset at age 4 and persistence into
    adulthood was reported in an Austrian individual homozygous for p.Arg122Gln,
    suggesting a possible extension of the phenotypic spectrum. Reported in a
    single individual to date.
  phenotype_term:
    preferred_term: Generalized-onset seizure
    term:
      id: HP:0002197
      label: Generalized-onset seizure
    onset:
      onset_category: CHILDHOOD
  frequency: VERY_RARE
  evidence:
  - reference: PMID:38286424
    reference_title: "A Homozygous PTRHD1 Missense Variant (p.Arg122Gln) in an Individual with Intellectual Disability, Generalized Epilepsy, and Juvenile Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Notably, she developed genetic generalized epilepsy at age 4, persisting
      into adulthood.
    explanation: >-
      Single-case report of generalized epilepsy; the authors themselves frame
      it as a potential extension of the spectrum, supporting the VERY_RARE band.

- category: Eye
  name: Exotropia
  description: >-
    Divergent strabismus, reported in all affected siblings of the Pakistani
    family and described by the authors as an unusual feature not previously
    reported in PTRHD1-related disease.
  phenotype_term:
    preferred_term: Exotropia
    term:
      id: HP:0000577
      label: Exotropia
  frequency: VERY_RARE
  evidence:
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Gait ataxia, exotropia, pectus excavatum, and prominent clavicles further
      widen the clinical phenotype.
    explanation: >-
      Reported in a single family as a phenotype-widening feature, supporting
      the VERY_RARE band.

- category: Musculoskeletal
  name: Pectus excavatum
  description: >-
    Depressed sternum with prominent clavicles, reported in the three examined
    siblings of the Pakistani family and not described in other PTRHD1 kindreds.
  phenotype_term:
    preferred_term: Pectus excavatum
    term:
      id: HP:0000767
      label: Pectus excavatum
  frequency: VERY_RARE
  evidence:
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients have exotropia and the three patients examined in detail have
      pectus excavatum and prominent clavicles.
    explanation: Documents the skeletal findings in a single reported family.

- category: Neurologic
  name: Postural tremor
  description: >-
    Postural tremor, listed by the monogenic-parkinsonism review among the
    variable complications of PTRHD1 disease and documented alongside rest
    tremor in the proband of the Iranian p.His53Tyr family.
  phenotype_term:
    preferred_term: Postural tremor
    term:
      id: HP:0002174
      label: Postural tremor
  evidence:
  - reference: PMID:34630269
    reference_title: "Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Phenotypes were variably complicated by muscle stiffness, postural tremor,
      pyramidal signs, sensory-motor polyneuropathy, behavioral disorders, and
      hypersomnia.
    explanation: >-
      Review names postural tremor among the variable complications of the
      PTRHD1 phenotype.
  - reference: PMID:27753167
    reference_title: "PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      presented with ID, muscle stiffness, rest and postural tremor, postural
      instability, gait disturbances, speech difficulties
    explanation: Documents postural tremor in the index Iranian proband.

- category: Neurologic
  name: Sensorimotor neuropathy
  description: >-
    Sensory-motor polyneuropathy is listed among the variable complications of
    the PTRHD1 phenotype. It is mechanistically notable because peripheral-nerve
    involvement is not part of the nigrostriatal or corticospinal arms curated
    here, and no nerve-conduction data have been published for any PTRHD1
    patient.
  phenotype_term:
    preferred_term: Sensory-motor polyneuropathy
    term:
      id: HP:0007141
      label: Sensorimotor neuropathy
  evidence:
  - reference: PMID:34630269
    reference_title: "Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Phenotypes were variably complicated by muscle stiffness, postural tremor,
      pyramidal signs, sensory-motor polyneuropathy, behavioral disorders, and
      hypersomnia.
    explanation: >-
      The only source for peripheral-nerve involvement in PTRHD1 disease; it is
      a narrative review listing it as a variable complication, with no counts
      and no primary electrophysiology, so no frequency band is asserted.

- category: Neurologic
  name: Hypersomnia
  description: >-
    Excessive sleepiness, reported as hypersomnia in the proband of the Iranian
    p.His53Tyr family and listed among the variable complications of the PTRHD1
    phenotype. Distinct from the sleep-onset insomnia reported with
    obsessive-compulsive disorder in the Omani family.
  phenotype_term:
    preferred_term: Hypersomnia
    term:
      id: HP:0001262
      label: Excessive daytime somnolence
  evidence:
  - reference: PMID:34630269
    reference_title: "Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Phenotypes were variably complicated by muscle stiffness, postural tremor,
      pyramidal signs, sensory-motor polyneuropathy, behavioral disorders, and
      hypersomnia.
    explanation: >-
      Review names hypersomnia among the variable complications of the PTRHD1
      phenotype.
  - reference: PMID:27753167
    reference_title: "PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      psychiatric symptoms such as anxiety, hypersomnia, and hypersexuality
    explanation: Documents hypersomnia in the index Iranian proband.

- category: Psychiatric
  name: Depression
  description: >-
    Depression is listed among the recurrent behavioral symptoms reported across
    PTRHD1 families. No counts are available.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other reported behavioral symptoms reported included depression, anxiety,
      sleep disturbances, and hypersexuality.
    explanation: Depression listed among the recurrent behavioral symptoms of the disorder.

- category: Neurologic
  name: Speech apraxia
  description: >-
    Apraxia of speech, reported among the early-onset behavioral and
    communication problems in the Pakistani family alongside stuttering and
    unclear language.
  phenotype_term:
    preferred_term: Apraxia of speech
    term:
      id: HP:0011098
      label: Speech apraxia
    onset:
      onset_category: CHILDHOOD
  frequency: VERY_RARE
  evidence:
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early onset behavioral problems in presented patients include attention
      deficit, hyperactivity, aggressive behavior and seclusion, apraxia of
      speech, stuttering, and somniloquy.
    explanation: >-
      Reported in a single family and not described in the ten previously
      reported families, supporting the VERY_RARE band.

- category: Neurologic
  name: Stuttering
  description: >-
    Stuttering with unclear language in the most severely affected sibling of
    the Pakistani family.
  phenotype_term:
    preferred_term: Stuttering
    term:
      id: HP:0025268
      label: Stuttering
    onset:
      onset_category: CHILDHOOD
  frequency: VERY_RARE
  evidence:
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      He stutters, has unclear language, and is hyperactive with recurrent
      episodes of aggressive behavior.
    explanation: >-
      Documents stuttering in one affected sibling of one family, supporting the
      VERY_RARE band.

progression:
- phase: Phase 1 - static neurodevelopmental phase
  age_range: Late infancy to childhood
  notes: >-
    Developmental milestones are delayed from late infancy; motor milestones may
    be mildly late (one proband sat at 10 months and walked at 20 months) and
    speech is markedly delayed. This resolves into a stable, NON-progressive
    impairment of intellectual development with behavioral abnormalities, which
    can remain the sole presentation for two to four decades. In some families
    (Omani, South African) childhood pyramidal signs - spasticity and
    hyperreflexia - accompany this phase and are themselves slowly progressive.
  evidence:
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early onset and nonprogressive ID in the four siblings were assessed as
      mild to moderate
    explanation: Establishes the static character of the first phase.
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All cases reported shared a consistent phenotype of delayed developmental
      milestones and moderate to severe ID. The onset of symptoms was present
      since late infancy.
    explanation: Fixes the late-infantile onset of the first phase.
- phase: Phase 2 - progressive motor-neurodegenerative phase
  age_range: Later childhood to fourth decade (most commonly third to fourth decade)
  notes: >-
    Progressive parkinsonism (bradykinesia, rest and postural tremor, variable
    rigidity and postural instability, gait disturbance) emerges after the
    static phase, frequently accompanied by late cognitive decline/dementia.
    Onset is variably penetrant and heterogeneous even within a single sibship:
    in one Omani family only one of four affected siblings had developed
    parkinsonism by the fourth decade, and in the Pakistani family the eldest
    sibling was the least affected. Motor features are levodopa-responsive in
    most reported patients.
  evidence:
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In all 10 families, onset of ID was early childhood, and in parkinsonism,
      later childhood to the fourth decade.
    explanation: Gives the onset window for the second phase across all reported families.
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Parkinsonism features developed during adulthood.
    explanation: Confirms adult onset of the motor phase in the Omani family.
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Intrafamilial and disease symptoms heterogeneity were noted, including the
      onset of parkinsonism symptoms.
    explanation: Documents the intrafamilial variability in timing of the second phase.

diagnosis:
- name: Biallelic PTRHD1 variant on exome, genome, or movement-disorder panel sequencing
  diagnosis_term:
    preferred_term: Whole Exome Sequencing
    term:
      id: NCIT:C101295
      label: Whole Exome Sequencing
  description: >-
    Diagnosis is genomic. There are no consensus clinical criteria and no
    biochemical or imaging biomarker. Suspicion should be raised by impaired
    intellectual development with behavioral abnormalities followed by
    early-onset parkinsonism, particularly with affected siblings or parental
    consanguinity; confirmation is a biallelic PTRHD1 variant on exome, genome,
    or a movement-disorder/Parkinson gene panel, with segregation testing in the
    family. Because the parkinsonian arm can appear decades after the
    neurodevelopmental one, PTRHD1 belongs on panels used for both indications.
  evidence:
  - reference: PMID:41722179
    reference_title: "Early-onset parkinsonism with intellectual disability in an Italian family associated with a PTRHD1 variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study expands the mutational and geographical spectrum of
      PTRHD1-related disorders and reinforces the inclusion of PTRHD1 in genetic
      screening panels for early-onset parkinsonism, particularly in individuals
      with intellectual disability and evidence of autosomal recessive
      inheritance.
    explanation: >-
      States the indication for PTRHD1 testing and the panel context in which
      the diagnosis is made.
  - reference: PMID:38286424
    reference_title: "A Homozygous PTRHD1 Missense Variant (p.Arg122Gln) in an Individual with Intellectual Disability, Generalized Epilepsy, and Juvenile Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Using diagnostic exome sequencing, we identified a homozygous missense
      variant (c.365G > A, p.(Arg122Gln)) in PTRHD1 (NM_001013663).
    explanation: >-
      Worked example of the diagnostic route: a homozygous PTRHD1 variant found
      on diagnostic exome sequencing.

- name: Exclusion of metabolic, structural, and cytogenetic mimics
  diagnosis_term:
    preferred_term: Laboratory Procedure
    term:
      id: NCIT:C25294
      label: Laboratory Procedure
  description: >-
    Because there is no PTRHD1-specific biomarker, the pre-genomic workup is one
    of exclusion. In the Omani proband an inborn-error-of-metabolism screen,
    thyroid function, creatine kinase, chromosomal microarray, and brain MRI
    were all normal - which is the expected pattern and does not argue against
    the diagnosis.
  evidence:
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The following investigations were within normal limits and included an
      inborn error of metabolism screen, thyroid function test, CK level,
      chromosomal microarray, and a brain magnetic resonance imaging (MRI)
      examination.
    explanation: >-
      Enumerates the exclusion workup that is normal in PTRHD1 disease.

imaging_findings:
- name: Unremarkable brain MRI
  modality: MRI
  description: >-
    Brain MRI has been grossly normal in reported patients, with no
    pathognomonic PTRHD1 pattern and no iron accumulation or other
    neurodegenerative signature described. The one detailed report notes that
    hippocampal detail could not be reliably assessed on its sequences, so a
    subtle mesial-temporal abnormality is not formally excluded. This is
    diagnostically important: a normal MRI does not exclude the diagnosis, and
    imaging serves mainly to exclude structural and metabolic mimics.
  evidence:
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The results of multiecho and multiplanar brain MRI were grossly
      unmarkable, but fine detail of hippocampal morphology could not be
      reliably evaluated due to suboptimal coronal coverage
    explanation: >-
      Documents a grossly normal brain MRI in four affected siblings, together
      with the authors' own caveat that hippocampal detail was not reliably
      assessable.
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The following investigations were within normal limits and included an
      inborn error of metabolism screen, thyroid function test, CK level,
      chromosomal microarray, and a brain magnetic resonance imaging (MRI)
      examination.
    explanation: >-
      Normal MRI plus normal metabolic and chromosomal-microarray workup in an
      Omani proband, underlining the genomic route to diagnosis.

treatments:
- name: Levodopa
  description: >-
    A monitored levodopa trial is the principal symptomatic option once
    parkinsonism becomes functionally limiting. Most reported PTRHD1 patients
    who developed parkinsonism in the third or fourth decade had
    levodopa-responsive symptoms, which is also the pharmacological basis for
    inferring a presynaptic nigrostriatal dopaminergic deficit. Quantitative
    response rates, durability, and dyskinesia risk have not been reported in
    this disorder, and at least one patient was unable to cooperate with a
    levodopa trial.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: levodopa
      term:
        id: CHEBI:15765
        label: L-dopa
  target_mechanisms:
  - target: Striatal Dopamine Deficiency and Basal Ganglia Motor Circuit Dysfunction
    description: >-
      Levodopa is decarboxylated to dopamine in surviving nigrostriatal
      terminals and other striatal cells, restoring striatal dopaminergic tone
      and correcting basal ganglia motor-circuit imbalance. It does not act on
      the upstream PTRHD1 lesion or on neuronal loss.
  evidence:
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Most of these patients developed levodopa‐responsive parkinsonism symptoms
      around the third and fourth decade.
    explanation: >-
      Documents levodopa responsiveness in most of the seven patients from the
      three families reported as of 2021. No quantitative response rate,
      durability, or dyskinesia-risk data exist for this disorder.
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      She was not cooperative for the levodopa trial and OCD treatment.
    explanation: >-
      Illustrates a practical limitation: behavioral and cognitive impairment
      can prevent a formal levodopa trial, which is part of why response data
      are sparse.

- name: Genetic Counseling and Cascade Testing
  description: >-
    Because transmission is biallelic and most reported families are
    consanguineous, genetic counseling for a 25% recurrence risk per pregnancy,
    carrier testing
    of at-risk relatives once the familial variant is known, and discussion of
    prenatal or preimplantation genetic testing are the principal preventive
    interventions.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:41722179
    reference_title: "Early-onset parkinsonism with intellectual disability in an Italian family associated with a PTRHD1 variant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study expands the mutational and geographical spectrum of
      PTRHD1-related disorders and reinforces the inclusion of PTRHD1 in genetic
      screening panels for early-onset parkinsonism, particularly in individuals
      with intellectual disability and evidence of autosomal recessive
      inheritance.
    explanation: >-
      Supports genomic testing (and hence counseling and cascade testing) as the
      actionable pathway in this recessive disorder.

- name: Multidisciplinary Supportive and Rehabilitative Care
  description: >-
    No disease-modifying therapy exists. Management is symptom-directed and
    lifelong: special educational placement and behavioral support for the
    developmental and psychiatric manifestations, speech and language therapy
    for the marked language delay, physiotherapy and mobility aids for
    spasticity and later parkinsonian gait impairment, and standard treatment of
    epilepsy and sleep disturbance where present. Longitudinal movement-disorder
    surveillance is warranted into adulthood because parkinsonism may emerge
    decades after the neurodevelopmental diagnosis.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:36699000
    reference_title: "Parkinsonism in Genetic Neurodevelopmental Disorders: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      and involvement of a movement disorder specialist may be considered
    explanation: >-
      Supports the longitudinal movement-disorder surveillance recommended here.
      It is class-level guidance for genetic neurodevelopmental disorders with
      parkinsonism (the group that includes PTRHD1); no PTRHD1-specific
      management study or guideline exists.
  - reference: PMID:36699000
    reference_title: "Parkinsonism in Genetic Neurodevelopmental Disorders: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      in view of the comorbidity in many GNDs, which may involve clinical
      experts from many subspecialties in addition to the family doctor and
      movement disorder specialist
    explanation: >-
      Supports the multidisciplinary framing of care at the level of the disease
      class; the individual components recommended here (special education,
      speech and language therapy, physiotherapy, antiseizure treatment) are
      standard practice extrapolated from the constituent phenotypes and are not
      separately evidenced for PTRHD1.
  notes: >-
    Deep brain stimulation is deliberately NOT listed as a treatment. No PTRHD1
    patient has been reported to undergo DBS, and its efficacy should not be
    assumed by analogy with PRKN- or PINK1-related parkinsonism: the motor
    syndrome here is frequently incomplete (rigidity and postural instability
    absent in at least one family), is accompanied by pyramidal signs and
    moderate-to-severe intellectual disability, and no dopaminergic imaging has
    ever confirmed a nigrostriatal deficit. This is recorded as a note rather
    than a treatment entry because there is no citable PTRHD1-specific source.

differential_diagnoses:
- name: PRKN-Related Juvenile Parkinson Disease
  description: >-
    The commonest autosomal recessive early-onset parkinsonism. Like PTRHD1
    disease it is recessive, levodopa-responsive, and third-decade in onset, and
    it also implicates the ubiquitin-proteasome system (parkin is an E3
    ubiquitin ligase).
  distinguishing_features:
  - >-
    PRKN disease is a comparatively pure parkinsonism without a preceding static
    neurodevelopmental phase: intellectual development and childhood milestones
    are normal, and behavioral abnormalities are not a defining early feature.
    PTRHD1 disease is defined by the childhood cognitive/behavioral phase that
    precedes motor onset by decades.
  evidence:
  - reference: PMID:34630269
    reference_title: "Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among AR parkinsonisms, forms caused by biallelic pathogenic variants in
      the PRKN, PINK1, and DJ-1 genes are thus far considered pure forms of
      EOPD.
    explanation: >-
      States the key discriminator: PRKN/PINK1/DJ-1 cause pure early-onset
      Parkinson disease, whereas PTRHD1 causes a complicated form.
- name: PARK7-Related Early-Onset Parkinson Disease
  description: >-
    Autosomal recessive early-onset Parkinson disease caused by biallelic
    PARK7/DJ-1 loss of function, with onset typically in the third decade and a
    high burden of psychiatric and cognitive non-motor features.
  distinguishing_features:
  - >-
    PARK7 disease is classified among the pure forms of early-onset Parkinson
    disease; its cognitive and psychiatric features accompany or follow motor
    onset rather than constituting a preceding static childhood
    neurodevelopmental phase, and pyramidal signs are not a defining feature.
  evidence:
  - reference: PMID:34630269
    reference_title: "Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among AR parkinsonisms, forms caused by biallelic pathogenic variants in
      the PRKN, PINK1, and DJ-1 genes are thus far considered pure forms of
      EOPD.
    explanation: Groups DJ-1/PARK7 with the pure, non-syndromic recessive parkinsonisms.
- name: Kufor-Rakeb syndrome
  description: >-
    ATP13A2-related autosomal recessive juvenile parkinsonism with pyramidal
    signs, supranuclear gaze palsy, and cognitive decline - one of the closest
    clinical mimics of PTRHD1 disease among the atypical juvenile parkinsonisms.
  distinguishing_features:
  - >-
    Kufor-Rakeb typically shows supranuclear vertical gaze palsy,
    facial-faucial-finger mini-myoclonus, and often brain iron accumulation on
    MRI, and its cognitive decline is progressive dementia rather than a static
    childhood intellectual impairment. Brain MRI in PTRHD1 disease is grossly
    normal.
  evidence:
  - reference: PMID:27753167
    reference_title: "PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Atypical juvenile parkinsonism (AJP) usually refers to a complex form of
      EOP that is inherited in a recessive manner and manifests with diverse
      neurological and psychiatric manifestations, including pyramidal signs,
      abnormalities of eye movements, depression, anxiety, psychosis, impulse
      control disorders, and intellectual disability (ID), among others.
    explanation: >-
      Defines the atypical juvenile parkinsonism class - including the
      ATP13A2/Kufor-Rakeb prototype with its eye-movement abnormalities - within
      which PTRHD1 disease must be distinguished.
  - reference: PMID:27753167
    reference_title: "PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To date, pathogenic mutations in at least eight different genes have been
      reported in AJP.
    explanation: >-
      Establishes the size of the atypical-juvenile-parkinsonism gene panel
      (ATP13A2, DNAJC6, FBXO7, PLA2G6, SPG11, SPG15, SYNJ1, VPS13C) that must be
      excluded before attributing disease to PTRHD1.
  - reference: PMID:34630269
    reference_title: "Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      VPS13C and PTRHD1 are mutated in families with EOPD complicated by
      pyramidal signs and cognitive involvement.
    explanation: >-
      Names VPS13C as the closest phenotypic comparator to PTRHD1 within the
      complicated recessive early-onset parkinsonisms - the two genes share the
      pyramidal-plus-cognitive complication that separates them from the pure
      PRKN/PINK1/DJ-1 forms. VPS13C has no dismech entry yet, so it is recorded
      here rather than as its own differential.
- name: Parkinsonism in other genetic neurodevelopmental disorders
  description: >-
    A broad and growing class in which parkinsonism emerges on a background of a
    genetic neurodevelopmental disorder - 69 disorders in 422 patients in the
    most recent systematic review, most frequently 22q11.2 deletion syndrome,
    beta-propeller protein-associated neurodegeneration, Down syndrome,
    cerebrotendinous xanthomatosis and Rett syndrome. PTRHD1 is itself one of
    the entities in this class.
  distinguishing_features:
  - >-
    Distinction is genomic rather than clinical: the syndromic context (facial
    dysmorphism, organ involvement, an MRI signature such as brain iron in BPAN,
    or a biochemical abnormality as in cerebrotendinous xanthomatosis) points to
    the alternative diagnosis, whereas PTRHD1 disease has a normal MRI, no
    dysmorphism, and a normal metabolic screen.
  evidence:
  - reference: PMID:36699000
    reference_title: "Parkinsonism in Genetic Neurodevelopmental Disorders: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The literature search yielded 208 reports for data-extraction, describing
      69 genetic disorders in 422 patients. The five most reported from most to
      least frequent were: 22q11.2 deletion syndrome, beta-propeller
      protein-associated neurodegeneration, Down syndrome, cerebrotendinous
      xanthomatosis, and Rett syndrome.
    explanation: Defines the differential class and its most frequent members.
- name: Parkinson's Disease
  description: >-
    Common, largely sporadic late-onset Parkinson disease. PTRHD1 has not been
    found to be associated with typical Parkinson disease in European, Chinese
    and Taiwanese case-control studies; the authors of the European study note
    that PTRHD1 variants may be either extremely rare in Parkinson disease or
    not associated at all, and call for larger non-European and family-trio
    studies.
  distinguishing_features:
  - >-
    Typical Parkinson disease lacks the preceding childhood neurodevelopmental
    and behavioral phase and lacks the recessive inheritance pattern; PTRHD1
    variants are not enriched in typical Parkinson disease cohorts, so PTRHD1
    testing is indicated only in the syndromic, recessive, early-onset context.
  evidence:
  - reference: PMID:34246528
    reference_title: "Analysis of PTRHD1 common and rare variants in European patients with Parkinson's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our results show no association between PTRHD1 and PD risk or AAO. We
      conclude that PTRHD1 does not play a major role in PD in the European
      population.
    explanation: >-
      Large European case-control and GWAS analysis separating the PTRHD1
      syndromic entity from typical Parkinson disease.
  - reference: PMID:33004232
    reference_title: "Lack of PTRHD1 mutation in patients with young-onset and familial Parkinson's disease in a Taiwanese population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We did not find any pathogenic coding variants or previously reported
      mutations, suggesting that PTRHD1 mutations are rare in young-onset and
      familial PD in our population.
    explanation: >-
      Independent negative screen in 464 Taiwanese young-onset/familial PD
      participants.
  - reference: PMID:35848037
    reference_title: "Rare Variant Analysis of PTRHD1 in Parkinson's Disease in the Chinese Population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Three rare variants were identified, but rare variants of PTRHD1 were not
      enriched in PD.
    explanation: >-
      Independent negative burden test in a Chinese case-control cohort
      (1367 cases, 3298 controls).

discussions:
- discussion_id: ptrhd1_molecular_function_unknown
  kind: KNOWLEDGE_GAP
  prompt: >-
    What is the actual molecular function of human PTRHD1, given that the
    recombinant protein binds tRNA but has no peptidyl-tRNA hydrolase activity
    despite carrying the PTH2 domain that names the gene?
  attaches_to:
  - "pathophysiology#Impaired Ubiquitin-Proteasome Protein Quality Control"
  rationale: >-
    This is the central gap for the entire entry. The gene name and the
    ubiquitin-proteasome hypothesis both derive from the PTH2 domain, but the
    only direct biochemical characterization of the human protein found tRNA
    binding without hydrolase activity and concluded that PTRHD1 is not a
    peptidyl-tRNA hydrolase. No enzymatic activity, physiological substrate, or
    binding partner has been established for the human protein, and no
    disease-specific proteasome-function assay has been reported in PTRHD1
    patient neurons. Until this is resolved, every mechanistic node downstream of
    the genetic lesion is inferential, and the ubiquitin-proteasome model rests
    on yeast Pth2 homology rather than human data.
  proposed_experiments:
  - experiment_id: ptrhd1_interactome
    name: PTRHD1 neuronal interactome by AP-MS
    description: >-
      Determine binding partners of human PTRHD1 by affinity
      purification-mass spectrometry in neuronal cells, testing specifically for
      UBL-domain proteins (RAD23, UBQLN/DSK2 homologs) and proteasome subunits.
    decision_criterion: >-
      Recovery of UBL-domain proteins or proteasome subunits as reproducible
      specific interactors would support the ubiquitin-proteasome model; their
      absence alongside recovery of ribosome/tRNA-handling partners would favor
      a translation-associated quality-control function instead.
  - experiment_id: ptrhd1_proteasome_activity
    name: Proteasome function in patient-derived neurons
    description: >-
      Measure proteasome activity and steady-state polyubiquitinated-protein
      load in patient-derived fibroblasts and iPSC-derived cortical and midbrain
      dopaminergic neurons carrying p.Ala57Argfs*26 versus isogenic controls.
    decision_criterion: >-
      Reduced chymotrypsin-like proteasome activity or accumulation of
      polyubiquitinated protein in patient neurons would upgrade the
      Impaired Ubiquitin-Proteasome Protein Quality Control node from
      HYPOTHETICAL toward ESTABLISHED.
  - experiment_id: ptrhd1_null_vs_truncation
    name: Null versus stable-truncation allele comparison
    description: >-
      Test whether the stable truncated p.Ala57Argfs*26 protein acts as a null
      or exerts a distinct (dominant-negative or neomorphic) activity, by
      comparing a full knockout with a knock-in of the frameshift allele in the
      same isogenic background.
    decision_criterion: >-
      A phenotypic difference between full knockout and frameshift knock-in
      would show that the stable truncated protein is not simply a null, which
      would change how the Escape of Nonsense-Mediated Decay node is
      interpreted mechanistically.
  evidence:
  - reference: PMID:27235175
    reference_title: "Expression, purification, and buffer solubility optimization of the putative human peptidyl-tRNA hydrolase PTRHD1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Additionally, we report binding to tRNA but absence of peptidyl-tRNA
      hydrolase activity. Thus, PTRHD1 is not a Pth and the functional
      consequence of nucleotide binding remains undefined.
    explanation: >-
      The primary biochemical result establishing that the nominal function
      implied by the gene name does not hold, leaving the true function unknown.

- discussion_id: ptrhd1_no_neuropathology_or_dat_imaging
  kind: KNOWLEDGE_GAP
  prompt: >-
    Is the parkinsonism of PTRHD1 disease actually caused by nigrostriatal
    dopaminergic neurodegeneration? No neuropathological examination and no
    dopamine-transporter imaging study has ever been published for a
    PTRHD1-mutant individual.
  attaches_to:
  - "pathophysiology#Nigrostriatal Dopaminergic Neuron Degeneration"
  rationale: >-
    The Nigrostriatal Dopaminergic Neuron Degeneration node - and the
    conforms_to link to the parkinsonism_dopaminergic_degeneration module - is
    currently supported only indirectly, by levodopa responsiveness and by
    PTRHD1 expression in the substantia nigra, striatum and putamen. Brain MRI
    is grossly normal and DaTscan was explicitly unavailable in the one detailed
    report that mentions it. The distinction matters mechanistically: a
    genuinely degenerative nigral lesion would place this disorder alongside the
    other recessive early-onset parkinsonisms, whereas a developmental or
    functional dopaminergic deficit that becomes symptomatic with age would make
    it a different kind of entity - and this is exactly the neurodevelopment
    versus neurodegeneration question that makes the disorder interesting.
  proposed_experiments:
  - experiment_id: ptrhd1_dat_imaging
    name: Presynaptic dopaminergic imaging in PTRHD1 carriers
    description: >-
      Perform dopamine transporter SPECT (DaT-SPECT) or 18F-DOPA PET in
      PTRHD1-mutant individuals before and after the emergence of parkinsonism,
      to test for presynaptic dopaminergic denervation and to date its onset
      relative to motor symptoms.
    decision_criterion: >-
      Reduced striatal tracer binding that worsens with motor progression would
      confirm presynaptic nigrostriatal degeneration; normal binding in
      symptomatic individuals would refute the degenerative model and point to a
      postsynaptic or circuit-level mechanism.
  - experiment_id: ptrhd1_neuropathology
    name: Post-mortem neuropathology of a PTRHD1 brain
    description: >-
      Obtain post-mortem neuropathological examination of a PTRHD1-mutant brain,
      assessing nigral neuronal counts, alpha-synuclein/Lewy pathology, tau, and
      ubiquitin-positive inclusions.
    decision_criterion: >-
      Nigral neuronal loss would establish the degeneration node; the presence or
      absence of ubiquitin-positive inclusions would additionally test the
      ubiquitin-proteasome hypothesis directly in human tissue.
  evidence:
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DaTscan imaging is not available.
    explanation: >-
      Documents the absence of dopaminergic imaging in the one patient in whom
      parkinsonism was formally rated.
  - reference: PMID:36699000
    reference_title: "Parkinsonism in Genetic Neurodevelopmental Disorders: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Results of dopaminergic imaging and response to antiparkinsonian
      medication often supported the neurodegenerative nature of parkinsonism.
    explanation: >-
      Shows that the class-level expectation is neurodegeneration, which makes
      the absence of PTRHD1-specific imaging and pathology data a concrete,
      answerable gap rather than an open-ended question.

- discussion_id: ptrhd1_no_animal_or_cellular_model
  kind: KNOWLEDGE_GAP
  prompt: >-
    No animal or human cellular model of PTRHD1 deficiency has been reported
    that reproduces either arm of the biphasic phenotype. Can a model
    recapitulate the neurodevelopmental phase, the later motor-degenerative
    phase, or the transition between them?
  attaches_to:
  - "pathophysiology#PTRHD1 Biallelic Loss of Function"
  rationale: >-
    All published PTRHD1 work is human genetic or descriptive; the only
    laboratory studies are a recombinant-protein biochemistry paper and
    patient-lymphocyte transcript/protein analyses. Without a model system, the
    causal chain from the genetic lesion to either phenotype cannot be tested,
    and no therapeutic hypothesis beyond symptomatic levodopa can be evaluated.
    The biphasic course makes this disorder an unusually informative potential
    model for how a single locus can produce a static developmental deficit and
    a later progressive degeneration, which raises the value of building one.
  proposed_experiments:
  - experiment_id: ptrhd1_ipsc_neurons
    name: Isogenic iPSC-derived cortical and dopaminergic neuron models
    description: >-
      Generate isogenic PTRHD1-null and patient-allele knock-in human iPSC lines
      and differentiate them to cortical neurons and midbrain dopaminergic
      neurons, phenotyping neurite development, synapse formation, proteasome
      function, and long-term survival under stress.
    decision_criterion: >-
      A developmental phenotype in cortical neurons together with a
      later-emerging survival deficit in dopaminergic neurons would reproduce the
      biphasic human course in vitro and validate the two-arm pathograph.
  - experiment_id: ptrhd1_vertebrate_model
    name: Aged vertebrate PTRHD1 loss-of-function model
    description: >-
      Create PTRHD1 knockout and knock-in vertebrate models (mouse and/or
      zebrafish) with longitudinal cognitive, behavioral, and motor phenotyping
      into aged animals to test whether a late motor phase emerges on a
      developmental background.
    decision_criterion: >-
      Emergence of a late motor phenotype on a background of early cognitive or
      behavioral abnormality would establish the first animal model of the
      neurodevelopment-to-neurodegeneration transition for this gene.
  evidence:
  - reference: PMID:34765690
    reference_title: "Biallelic PTRHD1 Frameshift Variants Associated with Intellectual Disability, Spasticity, and Parkinsonism."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      However, to date, functional studies of the reported variants and studies
      of patients' derived cells were not performed.
    explanation: >-
      Scopes the gap to the pre-2021 literature: at the time of this report no
      functional study of any PTRHD1 disease allele had been performed. This
      same paper then supplied the first patient-derived-cell data (NMD escape,
      stable truncated protein), but no animal model and no engineered cellular
      model of PTRHD1 deficiency has been reported before or since.

- discussion_id: ptrhd1_parkinsonism_penetrance
  kind: OPEN_QUESTION
  prompt: >-
    Is the parkinsonian arm incompletely penetrant, or merely very late, so that
    all biallelic carriers would eventually develop it if followed long enough?
  attaches_to:
  - "pathophysiology#Nigrostriatal Dopaminergic Neuron Degeneration"
  rationale: >-
    Reports differ. Some describe parkinsonism as variably penetrant; in one
    Omani family only one of four affected siblings had developed mild
    parkinsonism by the fourth decade, and in an Iranian family the affected
    individuals were reported with intellectual disability manifestations. Yet
    the longest-followed kindred showed motor signs appearing only at ages
    34-48, with the authors concluding that gait problems may not be evident
    until towards the end of the fourth decade. Distinguishing true incomplete
    penetrance from ascertainment at too young an age changes both counseling
    and the interpretation of the mechanism (a stochastic degenerative threshold
    versus an obligate but slow decline).
  proposed_experiments:
  - experiment_id: ptrhd1_penetrance_cohort
    name: Prospective re-examination of known PTRHD1 kindreds
    description: >-
      Systematic prospective re-examination of all reported PTRHD1 kindreds at
      5-year intervals with standardized movement-disorder assessment, to
      establish age-specific penetrance curves for parkinsonism.
    decision_criterion: >-
      A penetrance curve approaching 100% by the fifth or sixth decade would
      support age-dependent rather than incomplete penetrance; a plateau well
      below 100% would establish genuinely incomplete penetrance and motivate a
      search for modifiers.
  evidence:
  - reference: PMID:41918506
    reference_title: "Homozygous PTRHD1 Mutation in Intellectual Disability and Atypical Parkinsonism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our findings reveal that not all PTRHD1 mutations manifest with muscle
      rigidity and postural instability and confirm that gait problems may not
      be evident until towards the end of the fourth decade.
    explanation: >-
      Supports the very-late-rather-than-absent interpretation, and documents
      the incomplete parkinsonian syndrome.
  - reference: PMID:34816696
    reference_title: "The PTRHD1 Mutation in Intellectual Disability."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our findings are in agreement with the clinical spectrum of PTRHD1
      mutations; however, our affected individuals suffer from ID
      manifestations.
    explanation: >-
      A family in whom intellectual disability was the reported manifestation,
      without documented parkinsonism, supporting variable expression of the
      motor arm.
📚

References & Deep Research

References

4
PMID:34630269
Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings
No top-level findings curated for this source.
PMID:36699000
Parkinsonism in Genetic Neurodevelopmental Disorders: A Systematic Review
No top-level findings curated for this source.
PMID:29143421
PTRHD1 and possibly ADORA1 mutations contribute to Parkinsonism with intellectual disability
No top-level findings curated for this source.
PMID:27134041
Mutation in ADORA1 identified as likely cause of early-onset parkinsonism and cognitive dysfunction
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 7 citations 2026-08-15T08:40:21.881974

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Neurodevelopmental Disorder with Early-Onset Parkinsonism and Behavioral Abnormalities
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Neurodevelopmental Disorder with Early-Onset Parkinsonism and Behavioral Abnormalities covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Neurodevelopmental Disorder with Early-Onset Parkinsonism and Behavioral Abnormalities

Executive summary and evidence limitations

This is an ultra-rare autosomal-recessive neurodevelopmental–neurodegenerative disorder caused by biallelic PTRHD1 variants. The characteristic sequence is childhood developmental/cognitive impairment, often with behavioral abnormalities, followed in adolescence or early adulthood by progressive parkinsonism. The evidence base remains exceptionally small: the principal reviews describe two consanguineous Iranian families and one sub-Saharan African kindred, with motor onset generally between 20 and 30 years. Accordingly, frequencies below are qualitative rather than population estimates. (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)

Open Targets maps the entity to MONDO:0958323 and identifies PTRHD1 as the principal target. It also returns CENPO with weaker evidence, apparently reflecting overlapping locus/variant records rather than an independently established second cause; CENPO should therefore not currently be curated as a definitive causal gene for this syndrome. (OpenTargets Search: Neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities)

Domain Summary
Disease name Neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities; a rare Mendelian syndrome linked primarily to biallelic PTRHD1 variation (established) (OpenTargets Search: Neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities, guadagnolo2021genotypephenotypecorrelationsin pages 7-8)
MONDO ID MONDO:0958323 (established disease identifier from Open Targets disease mapping) (OpenTargets Search: Neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities)
Causal gene PTRHD1 (peptidyl-tRNA hydrolase domain containing 1; OMIM gene noted in review as MIM 617342) is the principal associated gene; CENPO also appears in disease-target association resources but with weaker/overlapping evidence and should be treated cautiously for disease causality here (OpenTargets Search: Neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities, guadagnolo2021genotypephenotypecorrelationsin pages 7-8)
Inheritance Autosomal recessive / biallelic inheritance; reported affected individuals were from consanguineous or likely recessive families (established) (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)
Known human evidence / families Very limited human evidence: initially 3 families reported in the literature — 2 unrelated consanguineous Iranian families and 1 sub-Saharan African kindred — with a later 2024 single case carrying homozygous p.Arg122Gln and juvenile parkinsonism with ID/epilepsy (established for scarcity; exact total case count remains small) (OpenTargets Search: Neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities, guadagnolo2021genotypephenotypecorrelationsin pages 7-8)
Typical temporal course Childhood neurodevelopmental impairment (global developmental delay/intellectual disability ± behavioral abnormalities) followed by juvenile/early-adult parkinsonism, usually in the 20–30 year range in the earlier reports; progression appears chronic/progressive but detailed natural-history staging is not available (partly established, partly inferred) (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)
Core phenotypes with suggested HPO terms Intellectual disability HP:0001249; global developmental delay HP:0001263; behavioral abnormality HP:0000708; parkinsonism HP:0001300; bradykinesia HP:0002067; rigidity HP:0002063; tremor/postural tremor HP:0001337; pyramidal signs/spasticity HP:0002493 / HP:0001257; peripheral neuropathy HP:0009830; hypersomnia HP:0001262; generalized seizures/epilepsy reported in at least one later case HP:0002197 / HP:0001250 (phenotype set combines established reported findings with ontology suggestions) (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)
Variant classes Reported disease-associated variants include homozygous missense variants and a 28-nt frameshift deletion; later literature adds homozygous p.Arg122Gln in an individual with ID, generalized epilepsy, and juvenile parkinsonism (established at class level; exhaustive variant list not recoverable from currently available context) (OpenTargets Search: Neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities, guadagnolo2021genotypephenotypecorrelationsin pages 7-8)
Mechanism confidence Low-to-moderate confidence mechanism. Reviews propose loss of function of PTRHD1 and possible involvement in ubiquitin-proteasome / protein quality control biology, but direct disease-specific mechanistic validation remains sparse; no robust pathway model is established (conservative interpretation) (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)
Diagnosis Diagnosis is currently genomic: suspected from the syndromic combination of developmental disorder/behavioral abnormalities plus juvenile or early-onset parkinsonism, then confirmed by WES/WGS or targeted gene panel showing biallelic PTRHD1 variants. No disease-specific biomarker, clinical criteria, or pathognomonic laboratory test was identified (established scarcity; testing approach partly inferred from rare-disease practice) (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)
Treatment No disease-specific therapy established. Management is supportive/symptomatic, extrapolated from juvenile parkinsonism and neurodevelopmental care. Published disease-specific quantitative data on levodopa response, DBS, rehabilitation outcomes, or genotype-guided treatment were not identified in the available evidence base (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)
Epidemiology Ultra-rare; only a handful of families/cases reported. No reliable prevalence, incidence, carrier frequency, penetrance, sex ratio, or population-based estimates are available (established evidence gap) (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)
Trials No relevant disease-specific interventional clinical trials identified for PTRHD1-related disease; no gene therapy, RNA therapy, or targeted experimental program was found in the searched trial resources (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)
Major evidence gaps Missing or very limited data on: full variant spectrum; allele frequencies; penetrance/expressivity; MRI/DAT-SPECT patterns; longitudinal prognosis/survival; treatment response rates; QoL; environmental modifiers; protective factors; epigenetics; transcriptomics/proteomics/metabolomics; and validated animal/cellular disease models (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)

Table: This table provides a compact knowledge-base summary of PTRHD1-related neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities. It emphasizes established facts, flags inferred points conservatively, and highlights major evidence gaps for curation and future research.

1. Disease information

Definition. PTRHD1-related neurodevelopmental disorder is a Mendelian condition combining developmental delay or intellectual disability and behavioral disturbance with juvenile/early-onset parkinsonism. Reported associated findings include pyramidal signs, postural tremor, sensorimotor polyneuropathy, hypersomnia, and, in a later case, generalized epilepsy. (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)

Identifiers and nomenclature

  • MONDO: MONDO:0958323.
  • Gene: PTRHD1, peptidyl-tRNA hydrolase domain containing 1; gene MIM *617342 is reported in the reviewed literature.
  • Common names: “PTRHD1-related neurodevelopmental disorder,” “PTRHD1-related intellectual disability and parkinsonism,” “autosomal-recessive intellectual disability and parkinsonism,” and “PTRHD1-related juvenile-onset parkinsonism.”
  • OMIM disease number, Orphanet number: not established from the retrieved evidence and should be verified directly before database import.
  • ICD-10/ICD-11 and MeSH: no disease-specific code or heading was identified. General coding would necessarily use intellectual-disability/developmental-disorder and parkinsonism codes and would lose etiologic specificity.

The source evidence is principally individual patients and pedigrees reported in primary publications, subsequently aggregated by reviews and disease databases. It is not based on EHR-scale cohorts or population registries. Open Targets links the disease association to PMIDs 27134041, 27753167, 29143421, 30398675, 34765690, and 34816696. (OpenTargets Search: Neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities)

2. Etiology, risk, and protective factors

The primary cause is germline biallelic PTRHD1 variation, consistent with autosomal-recessive inheritance. Reported classes include homozygous missense substitutions and a homozygous 28-nucleotide frameshift deletion; loss of function is the leading disease model. (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)

Risk factors:

  • Carrying two pathogenic/likely pathogenic PTRHD1 alleles is the only established causal risk factor.
  • Parental consanguinity increases the probability that both parents carry the same rare allele; two foundational Iranian families were consanguineous. (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)
  • No validated susceptibility loci, modifier genes, sex effect, environmental toxin, infectious trigger, lifestyle factor, or occupational exposure has been demonstrated specifically for this disorder.

Protective factors and gene–environment interactions: none are known. Protective associations described for idiopathic Parkinson disease must not be transferred to this monogenic childhood-onset syndrome without evidence. No PTRHD1-specific G×E study was found.

3. Phenotypes

The phenotype is heterogeneous, and denominators are too small for reliable percentages. Suggested ontology annotations are:

  • Global developmental delay — HP:0001263; childhood onset; probably common in the neurodevelopmental presentation.
  • Intellectual disability — HP:0001249; childhood onset, variable severity; a defining recurrent feature.
  • Behavioral abnormality — HP:0000708; type and severity incompletely standardized.
  • Parkinsonism — HP:0001300; usually begins around 20–30 years in the initial families and appears progressive. Core components may be annotated as bradykinesia HP:0002067, rigidity HP:0002063, and tremor HP:0001337. (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)
  • Muscle stiffness/rigidity — HP:0002063.
  • Postural tremor — HP:0002174 is a more specific candidate if confirmed from the source record; otherwise use HP:0001337.
  • Pyramidal signs/spasticity — HP:0007256 or HP:0001257, depending on the documented examination.
  • Sensorimotor polyneuropathy — HP:0007141 or broader peripheral neuropathy HP:0009830.
  • Hypersomnia — HP:0001262.
  • Generalized epilepsy/seizures — HP:0002197/HP:0001250; reported in a 2024 individual and not yet established as universal.

Effects on quality of life have not been quantified with EQ-5D, SF-36, PROMIS, or a disease-specific instrument. Nevertheless, the combination of cognitive impairment, behavioral disturbance, parkinsonism, and neuropathy plausibly impairs education, independent living, mobility, communication, employment, and caregiver burden. That functional interpretation is clinically reasonable but has not been measured in a PTRHD1 cohort.

4. Genetic and molecular information

Causal gene: PTRHD1 is the supported causal gene. Open Targets lists ENSG00000184924 and five supporting evidence records. CENPO is listed at lower association strength, but current evidence does not establish it as a second monogenic cause. (OpenTargets Search: Neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities)

Variants: published disease alleles include homozygous missense variants and a 28-nt frameshift deletion. A 2024 report described homozygous p.Arg122Gln in an individual with intellectual disability, generalized epilepsy, and juvenile parkinsonism. Exact transcript-dependent HGVS expressions, genomic coordinates, ClinVar accessions, ACMG classifications, and gnomAD frequencies should be retrieved directly from ClinVar/gnomAD before variant-level import; they were not recoverable with sufficient certainty from the available full text. (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)

The variants are presumed constitutional germline, not somatic. The frameshift supports loss of function; the functional effect of individual missense alleles requires variant-specific evidence. No dominant-negative or gain-of-function mechanism has been demonstrated. No validated modifier gene, disease-specific methylation signature, histone alteration, recurrent translocation, inversion, aneuploidy, or pathogenic large copy-number change was established in the retrieved evidence.

5. Environmental information

No toxin, radiation exposure, pollution source, diet, smoking, alcohol use, exercise pattern, occupational exposure, or infectious agent has been causally connected to PTRHD1 disease. The disorder is not infectious, contagious, or zoonotic. Environmental Parkinson-disease associations should be treated only as differential-context information, not as evidence for this syndrome.

6. Mechanism and pathophysiology

PTRHD1 encodes a small protein containing a putative peptidyl-tRNA-hydrolase domain. Reviews propose that pathogenic variants impair PTRHD1 function and may disturb the ubiquitin–proteasome/protein-quality-control system. Direct biochemical confirmation in disease-relevant human neurons remains limited. (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)

A cautious causal model is:

  1. Upstream: biallelic pathogenic PTRHD1 variants reduce or alter PTRHD1 protein function.
  2. Intermediate, provisional: defective protein-quality control and/or peptidyl-tRNA-related processing leads to cellular proteostasis stress.
  3. Cellular vulnerability: developing neural circuits produce intellectual and behavioral manifestations; later dysfunction or loss in motor circuits produces parkinsonism.
  4. Downstream: basal-ganglia motor-network dysfunction manifests as bradykinesia, rigidity, and tremor, with possible corticospinal and peripheral-nerve involvement.

Only step 1 and the genotype–phenotype relationship are firmly supported; the intervening molecular chain remains hypothetical. Suggested terms include GO:0006511 ubiquitin-dependent protein catabolic process, GO:0051603 proteolysis involved in cellular protein catabolic process, GO:0006457 protein folding, and GO:0000502 proteasome complex. These are mechanism-oriented suggestions, not experimentally validated PTRHD1 disease annotations.

Candidate cell types are midbrain dopaminergic neuron (CL:0000700), cortical neuron (CL:0000540), and peripheral neuron (CL:0000533). Relevant subcellular candidates include cytosol (GO:0005829) and proteasome complex (GO:0000502). No disease-specific single-cell, spatial-transcriptomic, transcriptomic, proteomic, metabolomic, lipidomic, CRISPR-screen, or integrated multi-omic dataset was identified.

7. Anatomical structures affected

The primary system is the nervous system. Clinical parkinsonism implicates bilateral basal-ganglia and nigrostriatal circuitry, while developmental/cognitive features implicate cerebral networks. Pyramidal signs suggest corticospinal-system involvement, and sensorimotor polyneuropathy indicates peripheral nervous-system involvement. These are cliniconeuroanatomical inferences; disease-specific neuropathology is unavailable.

Suggested anatomical terms include brain UBERON:0000955, cerebral cortex UBERON:0000956, basal ganglion UBERON:0002420, substantia nigra UBERON:0002038, striatum UBERON:0002435, spinal cord UBERON:0002240, and peripheral nerve UBERON:0001021. Parkinsonism normally reflects bilateral network dysfunction, but systematic lateralization data are absent.

8. Temporal development

The recognizable pattern is childhood neurodevelopmental impairment followed by juvenile or early-adult parkinsonism. Initial family reports place motor onset broadly at 20–30 years. (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)

The condition appears chronic and progressive rather than episodic or relapsing-remitting, but no validated stages, progression rate, median duration, remission rate, or critical therapeutic window has been defined. Developmental surveillance should continue into adulthood because parkinsonism may emerge well after the initial neurodevelopmental diagnosis.

9. Inheritance and population

Inheritance is autosomal recessive. Foundational evidence came from two unrelated consanguineous Iranian families and one sub-Saharan African kindred. The ascertainment pattern supports homozygosity-by-descent in some families but does not establish an ethnic restriction. (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)

Prevalence, incidence, carrier frequency, sex ratio, penetrance, age-dependent penetrance, founder effects, and geographic variant frequencies are unknown. Expressivity is evidently variable because neurological accompaniments differ among reports. Genetic anticipation is not expected for the known sequence-variant mechanism and has not been reported. Germline mosaicism has not been documented but cannot be excluded in recurrence counseling.

For two confirmed carrier parents, the standard autosomal-recessive risk per pregnancy is 25% affected, 50% carrier, and 25% unaffected/non-carrier, assuming parentage and variant interpretation are secure.

10. Diagnostics

There are no standardized disease-specific clinical criteria. Suspicion should be raised by developmental delay/intellectual disability with behavioral abnormalities followed by juvenile parkinsonism, particularly in a consanguineous family or among affected siblings.

Recommended testing strategy:

  1. Neurologic, developmental, psychiatric/behavioral, sleep, and peripheral-nerve assessment.
  2. Brain MRI to exclude structural, metabolic, and neurodegenerative mimics; no pathognomonic PTRHD1 MRI pattern is established.
  3. EEG if seizures or regression occur; EMG/nerve-conduction studies if neuropathy is suspected.
  4. First-line genomic testing with a neurodevelopmental/movement-disorder panel or trio/family whole-exome sequencing that includes PTRHD1 and copy-number analysis.
  5. Whole-genome sequencing when exome/panel testing is negative, particularly to detect noncoding or structural variants.
  6. Confirm candidate variants by an orthogonal method and perform segregation testing. RNA studies may help evaluate splice variants but are not validated clinical biomarkers.

CMA is useful when a broader developmental phenotype suggests a copy-number disorder, but karyotyping and FISH are low-yield unless cytogenetic abnormalities are suspected. Mitochondrial DNA and repeat-expansion testing are differential-driven rather than PTRHD1-specific.

Important differentials include PRKN-, PINK1-, PARK7-, ATP13A2-, FBXO7-, DNAJC6-, SYNJ1-, PLA2G6-, RAB39B-, and WARS2-related disease; Wilson disease; dopa-responsive dystonia; mitochondrial and lysosomal disorders; neurodegeneration with brain iron accumulation; and medication-induced parkinsonism. The 2023 systematic review emphasizes that parkinsonism is increasingly recognized across genetic neurodevelopmental disorders, supporting broad genomic rather than narrowly phenotypic evaluation. No validated blood, CSF, imaging, proteomic, or metabolomic biomarker exists for PTRHD1 disease.

11. Outcome and prognosis

No 5- or 10-year survival estimates, mortality rates, or life-expectancy data exist. The principal morbidity is lifelong cognitive/developmental disability compounded by progressive motor impairment, behavioral symptoms, sleep disturbance, and occasionally neuropathy or epilepsy. Recovery of the underlying genetic disorder is not documented. Prognostic biomarkers and validated predictors of progression are absent.

12. Treatment and current implementation

No disease-modifying or regulatory-approved PTRHD1-specific therapy exists. No relevant PTRHD1-specific interventional trial was identified in the trial search.

Care is therefore multidisciplinary and symptom-directed:

  • A monitored levodopa/carbidopa trial is reasonable for function-limiting parkinsonism, but PTRHD1-specific response rates, durability, and dyskinesia risks are not quantified.
  • Physical therapy, gait/balance training, occupational therapy, speech-language therapy, assistive communication, and mobility devices should be individualized.
  • Educational and behavioral supports are required for developmental and psychiatric manifestations.
  • Treat epilepsy, neuropathic symptoms, sleep disturbance, constipation, dysphagia, and nutrition problems according to standard practice.
  • Deep-brain stimulation has no established PTRHD1-specific evidence and should not be assumed effective merely from experience in other genetic parkinsonisms.

Suggested NCIt concepts include Levodopa (NCIt drug concept), Carbidopa, Physical Therapy, Occupational Therapy, Speech Therapy, Genetic Counseling, and Deep Brain Stimulation; exact NCIt identifiers should be resolved through the current NCIt release before ingestion.

There is no established gene replacement, CRISPR, ASO, siRNA, mRNA, cell therapy, or pharmacogenomic algorithm. Open Targets supports PTRHD1 as the biological target but does not identify a validated therapeutic program. (OpenTargets Search: Neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities)

13. Prevention

There is no lifestyle, vaccine, environmental, or drug-based primary prevention for an individual who has inherited two pathogenic alleles. Relevant prevention is reproductive and complication-focused:

  • Genetic counseling and cascade testing of at-risk relatives.
  • Carrier testing after familial variants are established.
  • Prenatal diagnosis or preimplantation genetic testing where legally and ethically acceptable.
  • Early developmental intervention and longitudinal movement-disorder surveillance.
  • Tertiary prevention through fall reduction, aspiration surveillance, nutrition support, seizure control, and maintenance of mobility.

Population or newborn screening is not justified because prevalence, test performance, natural history, and benefits of presymptomatic treatment are unknown.

14. Other species and natural disease

No naturally occurring veterinary analogue attributable to an orthologous PTRHD1 defect was identified. Therefore, no affected breed, OMIA syndrome, zoonotic potential, or cross-species transmission applies. Orthologues likely occur broadly across vertebrates, but NCBI Gene and Taxon identifiers should be verified directly for each species before curation.

15. Model organisms and research priorities

No validated PTRHD1 knockout/knock-in mouse, rat, zebrafish, Drosophila, C. elegans, organoid, or patient-iPSC model that robustly reproduces both neurodevelopmental impairment and juvenile parkinsonism was identified. This is a major translational gap.

Priority models would include:

  • Isogenic human iPSC-derived cortical and midbrain dopaminergic neurons carrying patient alleles.
  • PTRHD1-null and missense knock-in vertebrate models with longitudinal motor, cognitive, sleep, and peripheral-nerve phenotyping.
  • Rescue experiments comparing wild-type PTRHD1 with patient variants.
  • Quantitative assays of proteasome activity, ubiquitinated proteins, stalled-translation products, cellular stress, neurite development, dopamine handling, and neuronal survival.

These studies are needed before the proposed proteostasis mechanism can be considered established or therapeutically actionable.

Recent developments and authoritative interpretation

The most relevant recent synthesis is the 2023 systematic review of parkinsonism in genetic neurodevelopmental disorders, which places PTRHD1 among a growing group in which parkinsonism emerges after an earlier developmental phenotype. The expert implication is practical: patients with genetically unexplained intellectual disability should receive long-term movement surveillance, while juvenile parkinsonism accompanied by developmental or behavioral abnormalities should prompt broad genomic testing.

A 2024 publication reported homozygous PTRHD1 p.Arg122Gln in an individual with intellectual disability, generalized epilepsy, and juvenile parkinsonism, extending the possible phenotype but remaining a single-patient observation. No 2023–2024 clinical trial, natural-history cohort, or disease-specific multi-omics study was found.

Key primary and review literature

  • Khodadadi H, et al. “PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism.” Movement Disorders. Published 2017. PMID: 27753167. DOI: https://doi.org/10.1002/mds.26824.
  • Kuipers DJS, et al. “PTRHD1 loss-of-function mutation in an African family with juvenile-onset parkinsonism and intellectual disability.” Movement Disorders. Published November 2018. PMID: 30398675. DOI: https://doi.org/10.1002/mds.27501.
  • Guadagnolo D, et al. Genotype-Phenotype Correlations in Monogenic Parkinson Disease. Frontiers in Neurology. Published September 2021. DOI: https://doi.org/10.3389/fneur.2021.648588. This review states that only three families were then documented and summarizes onset at 20–30 years with stiffness, postural tremor, pyramidal signs, sensorimotor polyneuropathy, behavioral disorders, and hypersomnia. (guadagnolo2021genotypephenotypecorrelationsin pages 7-8)
  • von Scheibler ENMM, et al. Parkinsonism in Genetic Neurodevelopmental Disorders: A Systematic Review. Movement Disorders Clinical Practice. Online publication October 2022; 2023 issue. DOI: https://doi.org/10.1002/mdc3.13577.
  • Gebert J, et al. A homozygous PTRHD1 missense variant (p.Arg122Gln) in an individual with intellectual disability, generalized epilepsy, and juvenile parkinsonism. Published 2024. DOI: https://doi.org/10.1055/a-2256-0722.

The retrievable abstract-level material did not contain exact sentences for most patient-level clinical claims; consequently, fabricated quotations have not been supplied. The PMID-linked primary-paper set and disease-target mapping are independently reflected in Open Targets. (OpenTargets Search: Neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities)

References

  1. (guadagnolo2021genotypephenotypecorrelationsin pages 7-8): Daniele Guadagnolo, Maria Piane, Maria Rosaria Torrisi, Antonio Pizzuti, and Simona Petrucci. Genotype-phenotype correlations in monogenic parkinson disease: a review on clinical and molecular findings. Frontiers in Neurology, Sep 2021. URL: https://doi.org/10.3389/fneur.2021.648588, doi:10.3389/fneur.2021.648588. This article has 92 citations and is from a peer-reviewed journal.

  2. (OpenTargets Search: Neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities): Open Targets Query (Neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities, 2 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 5
Resolved 5
Unresolved (possible confabulation) 0
Unverifiable 0

All extracted references resolved successfully.